<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model</title>
				<funder ref="#_Z4jpHxP">
					<orgName type="full">National Institutes of Health</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2013-07-25">2013 July 25.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Clint</forename><forename type="middle">E</forename><surname>Canal</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicinal Chemistry</orgName>
								<orgName type="department" key="dep2">College of Pharmacy</orgName>
								<orgName type="institution">University of Florida</orgName>
								<address>
									<settlement>Gainesville</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Drake</forename><surname>Morgan</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="institution">University of Florida</orgName>
								<address>
									<settlement>Gainesville</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Medicinal Chemistry</orgName>
								<orgName type="institution">University of Florida</orgName>
								<address>
									<addrLine>1600 SW Archer Rd</addrLine>
									<postCode>P5-07</postCode>
									<settlement>Gainesville</settlement>
									<region>FL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Department of Psychiatry</orgName>
								<address>
									<addrLine>1149 S. Newell Drive</addrLine>
									<postCode>L4-100</postCode>
									<settlement>Gainesville</settlement>
									<region>FL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Drug Testing and Analysis</title>
						<title level="j" type="abbrev">Drug Testing and Analysis</title>
						<idno type="ISSN">1942-7603</idno>
						<idno type="eISSN">1942-7611</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">4</biblScope>
							<biblScope unit="issue">7-8</biblScope>
							<biblScope unit="page" from="556" to="576"/>
							<date type="published" when="2013-07-25">2013 July 25.</date>
						</imprint>
					</monogr>
					<idno type="MD5">4D4F59BF21B845CA9CADDA8CBA190144</idno>
					<idno type="DOI">10.1002/dta.1333</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-04-21T20:07+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>5-HT2</term>
					<term>serotonin</term>
					<term>DOI</term>
					<term>HTR</term>
					<term>model</term>
					<term>2,5-dimethoxy-4-iodoamphetamine</term>
					<term>phenylisopropylamine</term>
					<term>psychedelic</term>
					<term>hallucinogen</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Two primary animal models persist for assessing hallucinogenic potential of novel compounds and for examining the pharmacological and neurobiological substrates underlying the actions of classical hallucinogens, the two-lever drug discrimination procedure and the drug-induced headtwitch response (HTR) in rodents.</s><s>The substituted amphetamine hallucinogen, serotonin 2 (5-HT 2 ) receptor agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI) has emerged as the most popular pharmacological tool used in HTR studies of hallucinogens.</s><s>Synthesizing classic, recent, and relatively overlooked findings, addressing ostensibly conflicting observations, and considering contemporary theories in receptor and behavioural pharmacology, this review provides an up-todate and comprehensive synopsis of DOI and the HTR model, from neural mechanisms to utility for understanding psychiatric diseases.</s><s>Also presented is support for the argument that, although both the two-lever drug discrimination and the HTR models in rodents are useful for uncovering receptors, interacting proteins, intracellular signalling pathways, and neurochemical processes affected by DOI and related classical hallucinogens, results from both models suggest they are not reporting hallucinogenic experiences in animals.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A brief chemistry and timeline of DOI</head><p><s>The hallucinogen, 2,5-dimethoxy-4-iodoamphetamine (DOI), is in the broad class of compounds called phenylalkylamines.</s><s>As the name suggests, phenylalkylamines consist of a phenyl ring attached to an alkyl chain that is attached to an amine.</s><s>Having a two-carbon chain, the alkyl in DOI is ethyl, rendering phenethylamine.</s><s>DOI has a methyl group attached to the α carbon of phenethylamine making its core structure, amphetamine (α-methylphenethylamine).</s><s>Attached to the 2 and 5 carbons of the phenyl ring are methoxy groups, and attached to the 4 carbon is iodine.</s><s>Amphetamine is also named phenylisopropylamine, and thus DOI is interchangeably identified as a substituted amphetamine or 1963, and its psychedelic effects in humans were discovered in 1964. <ref type="bibr" target="#b14">[15]</ref></s><s>The radiolabelled DOI, [ <ref type="bibr" target="#b124">[125]</ref> I]-DOI, which has high specific activity, was used to identify DOI binding sites in the rat brain in 1987. <ref type="bibr" target="#b15">[16]</ref></s><s>Since then, [ <ref type="bibr" target="#b124">[125]</ref> I]-DOI has become a frequently used tool to label high affinity (or non-hydrolyzable GTP-sensitive) 5-HT 2 (5-HT 2A , 5-HT 2B , or 5-HT 2C ) receptors for determination of ligand affinities of novel compounds in both recombinant DNA in vitro assays and ex vivo.</s><s>Also, competition binding using [ <ref type="bibr" target="#b124">[125]</ref> I]-DOI to label high affinity receptor binding sites may be part of a first-pass screen to test for 5-HT 2 agonist activity of novel compounds. <ref type="bibr" target="#b16">[17]</ref></s><s>I has become one of the most common tools to study mechanisms of classical hallucinogens in animals, with over 100 scientific publications reporting its use since 2000.</s><s>There are a few reasons for this: (1) of the substituted amphetamine hallucinogens, it is one of the few that is not specifically scheduled in the United States; (2) it is chemically stable even in solution; (3) it is relatively selective for activating 5-HT 2 receptors, activation of which likely underlies the psychoactive effects of classical hallucinogens. <ref type="bibr" target="#b17">[18]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacology of DOI</head><p><s>Most discussion regarding the pharmacology of DOI has centered on the 5-HT 2 G proteincoupled receptors (GPCRs) that include 5-HT 2A , 5-HT 2B , and 5-HT 2C subtypes.</s><s>]<ref type="bibr" target="#b20">[21]</ref> For example, using agonist radiolabelling, the K i values of (±)-DOI for human 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors were 0.7, 20, and 2.4 nM, respectively, <ref type="bibr" target="#b19">[20]</ref> and (±)-DOI's agonist potencies for stimulating recombinant human 5-HT 2A , 5-HT 2B , and 5-HT 2C receptor-mediated calcium signalling were 0.9, 1.4, and 7.9 nM, respectively. <ref type="bibr" target="#b18">[19]</ref></s><s>DOI has relatively low affinity (K i values greater than 1 mM) for all other 5-HT receptors investigated. <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref></s><s>Though DOI's affinity for 5-HT 3 receptors has not been reported to our knowledge, it is likely that DOI also has low affinity for this receptor. <ref type="bibr" target="#b1">[2]</ref></s><s>Unique among the 5-HT 2 receptor subtypes, the 5-HT 2C receptor can be edited post-transcriptionally to produce more than 20 different isoforms. <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref></s><s>DOI's potency (both affinity and efficacy) is affected by RNA editing of the 5-HT 2C receptor, having lower potency for fully edited compared to non-edited 5-HT 2C receptors. <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref></s><s>RNA editing of 5-HT 2C receptors also affects their desensitization and trafficking in the cell. <ref type="bibr" target="#b27">[28]</ref></s><s>hus, when examining the effects of DOI (and other compounds) at 5-HT 2C receptors, the isoform(s) studied should be taken into consideration.</s><s>This is feasible when assessing recombinant 5-HT 2C receptor isoforms in vitro, as expression of a specific isoform of the receptor is controlled by the experimenter.</s><s>In vivo, however, it is not possible to determine the specific 5-HT 2C receptor protein isoform(s) that are examined in the brain from a wildtype animal using common techniques (e.g.</s><s>radioligand binding).</s><s>For example, the relative proportion of different htr2C (genetic nomenclature for 5-HT 2C ) RNA isoforms that can be assessed by many existing methods does not directly correlate with the relative proportion of different 5-HT 2C receptor protein isoforms expressed in the cell membrane. <ref type="bibr" target="#b28">[29]</ref></s><s>This challenging issue warrants further attention.</s></p><p><s>Depending on the signalling pathway examined, DOI has been shown to be, in vitro, either a partial or a full agonist for 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors.</s><s>At recombinant human 5-HT 2 receptors, DOI generally behaves as a potent partial agonist for stimulating 5-HT 2mediated Ca ++ currents <ref type="bibr" target="#b18">[19]</ref> (used the 5-HT 2C-VSV isoform) and the phospholipase-C pathway, generating inositol phosphates (PLC-IP) <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref> (5-HT 2C isoform was not identified).</s><s>DOI is a full agonist for activating 5-HT 2C receptors coupled to the phospholipase-A (PLA) signalling pathway, <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32]</ref> and is a partial agonist for activating 5-HT 2A receptors coupled to PLA. <ref type="bibr" target="#b31">[32]</ref> DOI's efficacy for activating 5-HT 2 receptors is also related to receptor expression level, displaying greater efficacy in cells expressing relatively higher receptor densities.</s><s>For example, DOI behaves as a partial agonist (i.e.</s><s>53% efficacy relative to 5-HT) for 5-HT 2C-VSV receptor-mediated PLC-IP activity when receptors are expressed at ~300 fmol/mg, <ref type="bibr" target="#b32">[33]</ref> and as a full agonist (i.e.</s><s>101% efficacy relative to 5-HT) for 5-HT 2C-VSV receptor mediated PLC-IP activity when receptors are expressed at ~20 pmol/ mg, suggesting a significant receptor reserve. <ref type="bibr" target="#b33">[34]</ref></s><s>Ex vivo, DOI exhibits partial agonism at 5-HT 2 receptors, for example at 5-HT 2A receptors expressed on GABAergic interneurons in piriform cortex, <ref type="bibr" target="#b34">[35]</ref> and 5-HT 2C receptors expressed in choroid plexus. <ref type="bibr" target="#b9">[10]</ref></s><s>To our knowledge, DOI's efficacy for activating 5-HT 2B receptors in the brain has not been tested, likely owing to their scant expression in the rodent brain. <ref type="bibr" target="#b35">[36]</ref></s><s>I's pharmacology at receptors other than 5-HT receptors has received considerably less attention, but warrants discussion.</s><s>A recent report <ref type="bibr" target="#b22">[23]</ref> presents binding affinity (K i ) data for DOI (among many other psychedelic compounds) at more than 40 unique receptors known to be expressed in the brain.</s><s>DOI exhibited affinities, considered by the author to be noteworthy, for 19 receptors.</s><s>The highest K i value presented as noteworthy, however, was 2.72 μM, i.e.</s><s>DOI's affinity for the M1 muscarinic receptor (shown in the supplementary material), an affinity that is tacitly considered low or arguably not physiologically relevant (but see section on dosing issues).</s><s>The K i of DOI was less than 400 nM for only 6 receptors: 5-HT 2A (165.4 nM), 5-HT 2B (336 nM), 5-HT 2C (45.8 nM)  a , α 2A -adrenergic (73.7 nM), α 2B -adrenergic (340 nM), and β 2 -adrenergic (138.6 nM) receptors.</s></p><p><s>The reported affinities of DOI for α 2 -and β 2 -adrenergic receptors should be taken into account when considering DOI's behavioural effects.</s><s>For example , Benloucif et al. <ref type="bibr" target="#b36">[37]</ref> showed that DOI (above 12 nmol) increases dopamine release in the anterior striatum of anesthetized rats, an effect that was not blocked by the 5-HT 2 antagonist, ritanserin (4 a Notably, the K i values of DOI for 5-HT 2 receptors from <ref type="bibr" target="#b22">[23]</ref> are at least 2-fold higher than previous reports <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref> that used [ 3 H]-ketanserin (5-HT 2A ) or <ref type="bibr" target="#b2">[ 3</ref> nmol), suggesting it may be mediated by DOI acting on α 2 -adrenergic receptors, which are known to regulate dopamine release in brain tissue.</s><s>Also, cortical application of the α 1/2 adrenergic antagonist, prazosin, blocked the 5-HT releasing effect of DOI in the brain. <ref type="bibr" target="#b37">[38]</ref></s><s>e head-twitch response (HTR)</s></p><p><s>The first drug-elicited HTR To our knowledge, the first description of a drug-elicited HTR was reported in 1956 by Keller and Umbreit <ref type="bibr" target="#b40">[41]</ref> following intravenous administration of lysergic acid diethylamide (LSD) to mice.</s><s>They described an easily observed and quantifiable response that could be elicited by a light touch near the back of the head, similar to the reflexive response observed when the ear is touched or pinched (the pinna reflex response), or following LSD administration (which became 'permanent' in a subset of mice following an injection of indole followed by LSD).</s><s>In their words:</s></p><p><s>The response consists of a rapid and violent head shaking. . .</s><s>The head-twitch response does not occur in normal mice, and with a little experience the response is easy to detect.</s><s>It is only rarely that one is uncertain whether a particular animal possesses the head twitch or not. .</s><s>..Independent observations by different workers are remarkably consistent, so that this provided a suitable tool for the behavioral studies.</s><s>(p.</s><s>723)</s></p><p><s>In our experience, the HTR is indeed easily quantifiable, with a high concordance of counts between independent observers, and shows a reliable and remarkably low level of withinsubject (when animals are tested repeatedly) and between-subject (across animals within a particular treatment condition) variability.</s><s>Following this initial observation with LSD, Corne et al. <ref type="bibr" target="#b41">[42]</ref> demonstrated in a convincing and comprehensive manner that the serotonin precursor 5-hydroxytryptophan (which is decarboxylated into serotonin) elicits a HTR, and characterized the pharmacology of the response.</s><s>Several classes of drugs (including serotonin antagonists, antihistamines, and opioids) attenuated the response, MAO inhibitors (e.g.</s><s>harmine, iproniazid, pheniprazine, and tranylcypromine) potentiated the HTR, whereas other drugs had no effect (e.g.</s><s>barbituates).</s><s>Several years later, Corne and Pickering <ref type="bibr" target="#b42">[43]</ref> demonstrated that a variety of hallucinogens produce the HTR.</s><s>These drugs included the classical hallucinogens LSD, psilocybin, psilocin, N,N-dimethyltryptamine (DMT), and mescaline, as well as drugs such as phencyclidine (PCP), atropine, and yohimbine.</s><s>Interestingly, there was a correlation between potency of these compounds to elicit the HTR and the dose that was hallucinogenic in humans.</s><s>]<ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref> It should be noted that there are compounds from other pharmacological classes that also produce the HTR (e.g.</s><s>CB1 cannabinoid antagonists, see the section on Hallucinogenesis).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The first DOI-elicited HTR</head><p><s>To the best of our knowledge, Glennon et al. <ref type="bibr" target="#b4">[5]</ref> first studied DOI's behavioural properties in animals (rats), showing that DOI fully substituted for DOM in a drug discrimination task.</s><s>Two years later, based on a robust correlation between rat 5-HT 2 affinity and behavioural potency, Glennon et al. reported that the 5-HT 2 receptor was likely responsible for DOI's discriminative stimulus effects. <ref type="bibr" target="#b51">[52]</ref></s><s>With the discovery of 5-HT 2B and 5-HT 2C receptors, the 5-HT 2 receptor was reclassified as 5-HT 2A . <ref type="bibr" target="#b52">[53,</ref><ref type="bibr" target="#b53">54]</ref></s><s>Henceforth, when discussing the entire class of serotonin 2 receptors, i.e. 5-HT 2A , 5-HT 2B , and 5-HT 2C , 5-HT 2 will be used.</s><s>The first study examining the HTR elicited by DOI was reported by Arnt and Hyttel <ref type="bibr" target="#b54">[55]</ref> who used rats, and demonstrated dose-dependent increases in the number of head-twitches; this behavioural effect was blocked by administration of the fairly selective 5-HT 2A antagonist ketanserin, as well as the 5-HT 1A agonist 8-OH-DPAT.</s><s>Later studies confirmed 5-HT 2A receptors are the primary, direct mediators of the response, while 5-HT 1A receptors perform a modulatory function.</s><s>Many investigators describe the HTR effect in the rat as a 'head shake', however, it appears to be essentially the same response as the HTR in mice, at least in regards to similarity in appearance and 5-HT 2A receptor dependence.</s><s>A report by Darmani et al. <ref type="bibr">[56]</ref> was the first to demonstrate a DOI-elicited HTR in the mouse.</s><s>In this paper, DOI produced dose-dependent increases in HTRs (tested up to 5.0 mg/kg), the (-) isomer was demonstrated to be more effective in eliciting an HTR, and the 5-HT 2A antagonists, ketanserin and spiperone, as well as the 5-HT 1A agonist, 8-OH-DPAT, attenuated the response.</s><s>Similar but less commonly studied 5-HT 2A receptor-dependent behavioural responses have been elicited in other species including the rabbit (head bobs <ref type="bibr" target="#b56">[57,</ref><ref type="bibr" target="#b57">58]</ref> ) and the least shrew. <ref type="bibr" target="#b58">[59]</ref></s><s>In contrast, there are several other behavioural responses elicited by serotonergic compounds that are not 5-HT 2A receptor dependent.</s><s>For example, the 'serotonin syndrome' consists of a number of responses (e.g.</s><s>flat body posture, hind limb abduction, forepaw treading, lower lip retraction, backwards walking) that are primarily a consequence of agonism at 5-HT 1 receptor subtypes. <ref type="bibr" target="#b59">[60]</ref></s><s>The 'ear-scratch response' observed in mice (and also elicited by DOI) appears to be primarily mediated by activation of 5-HT 2C receptors. <ref type="bibr" target="#b60">[61]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>How to quantify the HTR and dose-related effects</head><p><s>There are several methods that have been used to quantify drug-elicited HTRs.</s><s>Quantal methods determine the percentage of animals that show an HTR in a given period of time following particular treatments.</s><s>This allows a relatively high-throughput method of quantifying the HTR, as large groups of animals can be observed at the same time (e.g. for an extended discussion of these methods see Corne et al. <ref type="bibr" target="#b41">[42]</ref> ).</s><s>More commonly, a graded response is obtained simply by counting the number of HTRs observed in a single animal during a testing period; these data are obtained by trained observers either in real time, or video-recorded and later quantified.</s><s>Depending on the question of interest, either a single animal's behaviour will be observed over time (e.g. to determine the time-course of the drug effect; Figure <ref type="figure" target="#fig_1">2</ref>) <ref type="bibr" target="#b61">[62,</ref><ref type="bibr" target="#b62">63]</ref> or more commonly a particular set of pretreatment and observation times are established.</s><s>As an example, we and other investigators have adopted a protocol in which DOI is administered 10 min before the testing session, and then the mouse is observed for 10 min.</s><s>These parameters allow for quantification of a robust HTR with consistent frequency throughout the observation period.</s><s>]<ref type="bibr" target="#b65">[66]</ref><ref type="bibr" target="#b66">[67]</ref><ref type="bibr" target="#b67">[68]</ref><ref type="bibr" target="#b68">[69]</ref><ref type="bibr" target="#b69">[70]</ref><ref type="bibr" target="#b70">[71]</ref> Some investigators have reported biphasic dose-effect curves, i.e. increases followed by decreases in HTR frequency with increasing doses.</s><s>For example, Pranzatelli <ref type="bibr" target="#b71">[72]</ref> describes a 'descending limb' of the doseeffect curve from 12-20 mg/kg in rats, whereas Fantegrossi et al. <ref type="bibr" target="#b72">[73]</ref> describe peak HTRs at 1.0 mg/kg, and decreases in HTR frequency at 3.0 mg/kg in Swiss NIH mice.</s><s>The reasons for the differences in the shape of the dose-effect curve are not known, although species and strain differences are likely to contribute (see extensive discussion of some of these issues below).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of repeated administration</head><p><s>Most studies use a particular experimental subject one time, presumably to eliminate the potential influence of repeated drug administration (i.e. the development of tolerance or sensitization) and repeated exposure to the testing apparatus.</s><s>However, there have been a number of studies examining the effects of repeated DOI administration on HTR and subsequent sensitivity to DOI.</s><s>As observed following the administration of essentially all drugs, the pattern of behavioural effects and change in subsequent sensitivity depend on the dose administered, frequency of administration, and time since the last injection.</s><s>In early studies, it was demonstrated that a single injection of DOI (2.5 mg/kg) in mice results in tolerance to a second dose administered 24 h later, but 'supersensitivity' (an increase in responsiveness) to a second dose administered 48 h later. <ref type="bibr" target="#b60">[61,</ref><ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b69">70]</ref></s><s>To further investigate the effects of repeated drug exposure, 2.5 mg/kg DOI was administered daily for 13 days, and separate groups of mice were challenged following discontinuation of the chronic drug treatment.</s><s>Tolerance immediately developed to the effects of DOI as indicated by ~40-50% decrease in the number of DOI-elicited HTRs following a 24-h period.</s><s>This tolerance, however, disappeared over a 13-day period such that the number of HTRs increased and returned to control levels by day 6.</s><s>Following chronic administration, a challenge dose of DOI (2.5 mg/kg), after a 48-h abstinence period, revealed a 'supersensitivity' (i.e. increase in HTR) that lasted for approximately 1 week. <ref type="bibr" target="#b69">[70]</ref></s><s>In a more recent paper, Dougherty and Aloyo <ref type="bibr" target="#b73">[74]</ref> administered 1 mg/kg DOI daily for 8 days (and 0.75 mg/kg on the 9th day).</s><s>Tolerance (responding decreased by ~40-50%) developed following the first injection and was maintained throughout the 9-day testing period.</s><s>The reasons for the discrepancy between the maintenance of tolerance in this study and the loss of tolerance upon repeated administration in the earlier studies by Darmani et al. are unclear; however, the dose used in the earlier studies was significantly higher (2.5 versus 1.0 mg/kg) and different strains of mice (ICR versus CB57Bl/6 N) were used (see the section on species and strain differences for further discussion).</s><s>To our knowledge, no papers have examined the effects of DOI administered repeatedly every 48 h to determine whether the increased sensitivity is maintained over time.</s><s>However, it has been demonstrated that when DOI is administered at weekly intervals, there appears to be no change in sensitivity over the course of 4 weeks. <ref type="bibr" target="#b74">[75]</ref></s><s>his finding is important as it suggests that within-subject experiments could be conducted to allow animals to act as their own controls, potentially increasing statistical power and sensitivity to identifying treatment effects.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of various physiological and environmental factors</head><p><s>Age-Relatively few studies have examined the effects of non-pharmacological factors on the DOI-elicited HTR.</s><s>With regards to age, the dose-effect curve for DOI was shifted slightly downward (i.e.</s><s>DOI was less effective) in older (3-3½-month-old) animals relative to younger (5-6-week-old) animals; <ref type="bibr">[76]</ref> however, a relatively limited age range was examined.</s><s>Darmani et al. <ref type="bibr" target="#b76">[77]</ref> examined the ontogeny of various DOI-elicited behaviours and found that the HTR elicited by 1.0 and 2.5 mg/kg became apparent at 18 days of age and remained at high levels through 180 days of age; there were gradual non-significant decreases over time.</s><s>In a genetic model of aging, the senescence accelerated mouse-prone (SAMP) was significantly more sensitive to DOI (more than twice as many HTRs following 0.3 and 1.0 mg/kg) relative to SAM-resistant mice. <ref type="bibr" target="#b77">[78]</ref></s><s>1]<ref type="bibr" target="#b81">[82]</ref> Sex-Few studies have examined the influence of sex and/or oestrus cycle on the HTR.</s><s>In the Darmani paper described earlier, <ref type="bibr" target="#b76">[77]</ref> male and female mice were not differentially sensitive to DOI.</s><s>Using 5-HTP to elicit the HTR, Boulton and Handley <ref type="bibr" target="#b82">[83]</ref> demonstrated that males were more sensitive to the effects of 5-HTP, but that oestrus cycle had no effect on the female mice.</s><s>There are simply not enough data making direct comparisons to clearly identify the potential influence of sex and hormonal status on the DOI-elicited HTR.</s></p><p><s>Environmental factors-The effects of housing conditions (e.g. the number of animals per cage) on the DOI-elicited HTR were reported in one study. <ref type="bibr" target="#b83">[84]</ref></s><s>Grouped-housed animals (5-6 ddY mice per cage) were significantly less sensitive to (±)-DOI (2.5 mg/kg) relative to singly-housed mice (13 vs. 24 HTRs in a 10-min observation period).</s><s>These data contrast with a study showing that 5-HTP-elicited HTRs are extraordinarily low in singly-housed mice, and the frequency of the 5-HTP-induced HTRs increases along with the number of mice living in a particular group. <ref type="bibr" target="#b82">[83]</ref></s><s>However, in the first paper to describe the HTR, <ref type="bibr" target="#b40">[41]</ref> the authors noted that the HTR elicited by LSD was topographically identical to the HTR elicited by 'solitary confinement' (i.e.</s><s>moving an animal from group-housing to singlyhoused conditions).</s><s>Given that housing conditions and social ranking within a colony can have dramatic effects on the 5-HT 2A receptor system, <ref type="bibr" target="#b84">[85]</ref> a systematic study of the effects of these factors on the sensitivity to DOI would be useful.</s></p><p><s>Yamata et al. <ref type="bibr" target="#b85">[86]</ref> examined the effects of a number of 'stressors' on DOI-elicited responses in rats.</s><s>Tail pinch for 30 min, immobilization for 60 min, and repeated foot shock for 30 min rendered animals less sensitive to DOI.</s><s>Administration of diazepam (benzodiazepine receptor agonist) 5 min before the immobilization stress prevented this loss of sensitivity to DOI.</s><s>This effect was blocked by the co-administration of flumazenil (benzodiazepine inverse agonist).</s><s>Swim stress for 10 min similarly produced a decreased sensitivity to DOI, i.e. 64-73% decrease in HTRs depending on the time of observation. <ref type="bibr" target="#b86">[87]</ref></s><s>In apparent contrast to these findings, stress induced by 3 h of restraint enhanced sensitivity to the effects of 1.0 mg/kg (but not 2.0 mg/kg) DOI in rats. <ref type="bibr" target="#b87">[88]</ref></s><s>Interestingly, obese Zucker rats that have an overactive hypothalamic-pituitary-adrenal system, resulting in a model of 'hypercorticism' with chronic, high levels of circulating corticosterone (which generally increases in rodents when exposed to stressful conditions) show a dramatically attenuated response to DOI compared to lean littermates. <ref type="bibr" target="#b88">[89]</ref></s><s>Finally, a couple of other studies have failed to show any effect of stress on sensitivity to DOI. <ref type="bibr" target="#b85">[86,</ref><ref type="bibr" target="#b89">90]</ref> Receptor systems involved in the HTR induced by DOI</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5-HT 2A</head><p><s>Activation of the 5-HT 2A receptor is necessary for DOI's (and all other classical hallucinogens) head-twitch-inducing effects in rodents. <ref type="bibr" target="#b17">[18]</ref></s><s><ref type="bibr" target="#b92">[93]</ref> Briefly, the HTR in mice and rats (and the mole-like shrew) induced by DOI (and other serotonin-releasing compounds) is blocked by a plethora of relatively selective 5-HT 2A antagonists; mice lacking the 5-HT 2A receptor do not show an HTR to DOI; and restoration of 5-HT 2A receptors to cortical (presumably glutamate) neurons in 5-HT 2A receptor knockout mice restores the ability of DOI to induce an HTR in mice. <ref type="bibr">[94]</ref></s><s>Furthermore, blockade of 5-HT 2A receptors by one of the most selective 5-HT 2A receptor antagonists, M100907, <ref type="bibr" target="#b94">[95]</ref> occludes the discriminative stimulus effects of psychedelic amphetamines in rodents <ref type="bibr" target="#b17">[18]</ref> and monkeys, <ref type="bibr" target="#b95">[96]</ref> suggesting the 5-HT 2A receptor underlies the discriminative stimulus effects of psychedelic amphetamines across species.</s><s>Finally, modulation of the DOI HTR by any class of compounds, noted in the next several sections, can be blocked by selective 5-HT 2A antagonists.</s><s>Thus, the 5-HT 2A receptor is necessary for the DOI HTR, and most of the following receptors, and neurotransmitter systems are best considered modulators of the DOI HTR.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5-HT 2B</head><p><s>Owing to its relatively low expression level in the brain, <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b96">97,</ref><ref type="bibr" target="#b97">98]</ref> the 5-HT 2B receptor has not received much of the limelight as a possible regulator of the DOI-induced HTR.</s><s>We are unaware of papers reporting effects of selective 5-HT 2B receptor antagonists on the DOI HTR.</s><s>The DOI HTR-inducing effects have also not been described in 5-HT 2B receptor knockout mice.</s><s>Interestingly, although the ergoline analogue, lisuride, has 5-HT 2A receptor agonist activity, it does not produce the HTR, and some (but not all) studies show that it is a potent antagonist of 5-HT 2B receptors. <ref type="bibr" target="#b98">[99]</ref></s><s>Other studies suggest it is worth considering the 5-HT 2B receptor as a potential modulator of the behavioral effects of DOI.</s><s>For example, like 5-HT 2A and 5-HT 2C receptors, 5-HT 2B receptor affinity of hallucinogenic phenylisopropalamines is highly correlated with their human hallucinogenic potency. <ref type="bibr" target="#b19">[20]</ref></s><s>lso, recent studies with rats show that the 5-HT 2B receptor is required for the anorexient effects of the serotonin releaser dexfenfluramine <ref type="bibr" target="#b99">[100]</ref> and for the serotonin-releasing and hyperlocomotion effects of 3,4-methylenedioxymethamphetamine (MDMA), <ref type="bibr" target="#b100">[101]</ref> findings that argue brain 5-HT 2B receptors may be involved in cognitive and/or behavioural effects of psychoactive drugs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5-HT 2C</head><p><s>Concerning their putative roles in the behavioural effects of psychedelic phenylisopropalamines, of the three 5-HT 2 receptors, most contention emanates from the 5-HT 2C receptor.</s><s>A number of studies have substantiated a role, albeit a modulatory one, for the 5-HT 2C receptor. <ref type="bibr" target="#b64">[65,</ref><ref type="bibr" target="#b101">102,</ref><ref type="bibr" target="#b102">103]</ref></s><s>Like the other 5-HT 2 receptors, the potency of phenylisopropalamines is highly correlated with their affinities for 5-HT 2C receptors. <ref type="bibr" target="#b19">[20]</ref></s><s>lso, the hallucinogenic potency of DOI, DOB, DOM and MDA decreases in parallel with decreasing efficacy to activate 5-HT 2C receptors. <ref type="bibr" target="#b9">[10]</ref></s><s>The (-)-DOM discriminative stimuluspotentiating effects of citalopram, furthermore, are attenuated by the highly selective 5-HT 2C antagonist, SB242084, <ref type="bibr" target="#b103">[104,</ref><ref type="bibr" target="#b104">105]</ref> and mCPP, considered a selective, albeit poorly selective, 5-HT 2C agonist (relative to 5-HT 2A receptors), also potentiated the discriminative stimulus effects of (-)-DOM. <ref type="bibr" target="#b105">[106]</ref></s><s>garding the HTR in rats, direct frontal cortex injections of mCPP induced an HTR, an effect that was attenuated by systemic pretreatment with the selective 5-HT 2C receptor antagonist SDZ SER-082. <ref type="bibr" target="#b106">[107]</ref></s><s>Interestingly, mCPP was more potent and produced more HTRs than DOI when injected centrally, <ref type="bibr" target="#b106">[107]</ref> though its affinity and efficacy for stimulating 5-HT 2 receptors is substantially lower than DOI's. <ref type="bibr" target="#b21">[22]</ref></s><s>Also intriguing, when administered systemically, mCPP actually attenuates HTRs induced by a number of 5-HT 2A agonists, including DOI. <ref type="bibr" target="#b107">[108,</ref><ref type="bibr" target="#b108">109]</ref> Nevertheless, both the 5-HT 2B / 2C selective antagonist/inverse agonist, SB206553, <ref type="bibr" target="#b109">[110]</ref> and the 5-HT 2C antagonist, SB242084, attenuated the HTR elicited by DOI by 50% in C56BL/6J and DBA/2J mice, and the DOI HTR was attenuated by ~50% in 5-HT 2C knockout mice, relative to their wild-type littermates. <ref type="bibr" target="#b64">[65]</ref></s><s>Moreover, 5-HT 2C antagonists also attenuated the discriminative stimulus effects of (+/-)-DOI in C57Bl/6J mice. <ref type="bibr" target="#b110">[111]</ref></s><s>Collectively, these data suggest that activation of 5-HT 2C receptors regulates the HTR and a portion of the behavioural effects of phenylisopropalamines in mice and rats.</s><s>Nevertheless, caveats and conflicting data abound.</s></p><p><s>A role for the 5-HT 2C receptor in mediating some of the cognitive and behavioural effects of psychedelic amphetamines is usually downplayed due to observations of opposing actions of 5-HT 2A and 5-HT 2C receptors. <ref type="bibr" target="#b72">[73,</ref><ref type="bibr" target="#b111">112]</ref></s><s>Moreover, SB242084 did not affect a rat's ability to discriminate DOI, <ref type="bibr" target="#b10">[11]</ref> and did not block the HTR in rats elicited by DOI, <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b112">113]</ref> nor did SDZ SER-082, <ref type="bibr" target="#b106">[107]</ref> or the selective 5-HT 2B/2C receptor antagonist SB 200646A. <ref type="bibr" target="#b113">[114]</ref></s><s>urthermore, behavioural tolerance to DOI after chronic administration (i.e.</s><s>decreased discriminative stimulus effect), paralleled a decrease in 5-HT 2A receptor-binding sites in the cortex and claustrum, yet was not associated with a decrease in 5-HT 2C receptor-binding sites in the striatum or choroid plexus, determined by autoradiography. <ref type="bibr" target="#b10">[11]</ref></s><s>It should be noted, however, that quantification of 5-HT 2C -receptor binding sites (which are much fewer in number than 5-HT 2A receptor binding sites) in the cortex, which is arguably the site of action for the discriminative stimulus effects of DOI, <ref type="bibr" target="#b114">[115]</ref> could not be ascertained with this method. <ref type="bibr" target="#b10">[11]</ref></s><s>ding to these findings were reports that the selective 5-HT 2C agonists (relative to 5-HT 2A ), Ro 60-0175 and CP 809 101, <ref type="bibr" target="#b115">[116,</ref><ref type="bibr" target="#b116">117]</ref> did not induce an HTR in rats on their own, <ref type="bibr" target="#b112">[113,</ref><ref type="bibr" target="#b116">117]</ref> and actually dose-dependently decreased the (-)-DOI-elicited HTR in Swiss NIH mice (Ro 60-0175) <ref type="bibr" target="#b72">[73]</ref> and rats (CP 809 101). <ref type="bibr" target="#b116">[117]</ref></s><s>When co-administered with SB242084 to putatively unmask its agonist activity for 5-HT 2A receptors, Ro 60-0175 produced an HTR, though at a lower frequency than the HTR induced by DOI. <ref type="bibr" target="#b112">[113]</ref></s><s>Based on these data, and that SB242084 pretreatment in Swiss NIH mice can potentiate the maximum HTR induced by DOI by ~20%, <ref type="bibr" target="#b72">[73]</ref> it is inferred that 5-HT 2C receptor activation suppresses the psychoactive effects of DOI.</s><s>Further elaborating on this point, counts of HTRs with increasing doses of DOI in Swiss NIH mice reveals an inverted-U shaped dose-response curve, and experiments combining M100907 or SB242084 with (-)-DOI suggest that the ascending part of the curve, at low DOI doses (from 0.3 to 1 mg/kg), is due to activation of 5-HT 2A receptors, while the descending part of the curve, at high doses (from 1 mg/kg to 10 mg/kg), is due to increasing activation of 5-HT 2C receptors. <ref type="bibr" target="#b72">[73]</ref></s><s>How these data are reconciled with the similar agonist potencies and efficacies of DOI for both 5-HT 2A and 5-HT 2C receptors, and the reports of linear increases in hallucinogenic effects in humans with increasing doses of DOI, was not addressed.</s><s>These data may suggest, however, that the HTR response observed may not map to hallucinogenic activity in humans.</s><s>Nevertheless, in C57Bl/6J and DBA/2J mice, which show a more robust HTR to DOI than Swiss NIH mice, the DOI HTR dose-response curve increased linearly then plateaued at doses up to 12.8 mg/ kg. <ref type="bibr" target="#b64">[65]</ref></s><s>In this set of experiments, mice appeared sick at higher doses of DOI; thus, large doses were administered to only a few mice (unpublished observations).</s><s>Similar linear DOI HTR dose-response curves up to 5 mg/kg have also been reported in albino ICR mice. <ref type="bibr">[56]</ref></s><s>gain, strain and species differences appear to be major factors to consider when interpreting DOI HTR data.</s></p><p><s>It is also worth noting that 1-methylpsilocin is a 5-HT 2C agonist, with more than 50 times greater affinity and potency for activating human 5-HT 2C-INI compared to 5-HT 2A receptors, <ref type="bibr" target="#b117">[118]</ref> yet causes a dose-dependent increase in the HTR in C57Bl/6J mice, <ref type="bibr" target="#b46">[47]</ref> suggesting that 5-HT 2C receptor activation (if the pharmacology of 1-methylpsilocin at human receptors is recapitulated at mice receptors) does not suppress 5-HT 2A receptormediated HTRs.</s><s>Finally, the novel indazole 5-HT 2 agonist, AL-38022A, showed severalfold higher potency for human 5-HT 2C receptors (isoform unspecified), compared to 5-HT 2A and 5-HT 2B receptors, and yet fully generalized to the DOM stimulus in both rat and monkey drug discrimination studies. <ref type="bibr" target="#b95">[96]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5-HT 1</head><p><s>In the first papers describing the DOI-elicited HTR in rats and mice, the 5-HT 1A agonist 8-OH-DPAT was shown to attenuate the response. <ref type="bibr" target="#b54">[55,</ref><ref type="bibr">56]</ref></s><s>This finding was replicated a number of times, <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b68">69,</ref><ref type="bibr" target="#b108">109]</ref> including demonstration that direct infusion of 8-OH-DPAT into the medial prefrontal cortex inhibits the effects of systemically administered DOI. <ref type="bibr" target="#b106">[107]</ref></s><s>These findings have been extended to a number of relatively selective 5-HT 1A agonists, with varying degrees of efficacy, including buspirone, flesinoxan, MKC242, S14671, and S14506. <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b68">69,</ref><ref type="bibr" target="#b83">84]</ref></s><s>The effects of the non-selective 5-HT 1A/2 agonist 5-MeO-DMT are interesting in that this compound can produce HTRs when administered alone. <ref type="bibr" target="#b46">[47]</ref></s><s>When combined with DOI, however, 5-MeO-DMT dose-dependently decreases the number of DOI-elicited HTRs, <ref type="bibr">[56]</ref> an effect attributed to 5-MeO-DMT's agonist activity for 5-HT 1A receptors.</s><s>Antagonism of the 5-HT 1A receptor (e.g. with WAY-100635) fails to alter the DOI-elicited HTR. <ref type="bibr" target="#b68">[69,</ref><ref type="bibr" target="#b83">84,</ref><ref type="bibr" target="#b118">119]</ref></s><s>Endogenous 5-HT 1A receptor activity, thus, may be too low to affect DOI-induced 5-HT 2 receptor activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other 5-HT receptors and the serotonin transporter</head><p><s>In general, it appears that selective serotonin transporter inhibitors (i.e.</s><s>SSRIs), such as fluoxetine, imipramine, fluvoxamine, and citalopram, fail to alter the DOI-elicited HTR. <ref type="bibr" target="#b62">[63,</ref><ref type="bibr" target="#b119">120]</ref></s><s>However, if the target of these compounds (i.e. the serotonin transporter) is genetically deleted, the ability of DOI to elicit HTRs is greatly reduced and/or eliminated. <ref type="bibr" target="#b118">[119,</ref><ref type="bibr" target="#b120">121]</ref></s><s>This effect is attributed to adaptations, e.g.</s><s>desensitization and decreased expression of 5-HT 2A receptors, due to life-long elevated levels of serotonin.</s><s>Chronic administration of serotonin, norepinephrine transporter inhibitors (i.e.</s><s>SNRIs) decrease the DOI-elicited HTR. <ref type="bibr" target="#b121">[122,</ref><ref type="bibr" target="#b122">123]</ref></s><s>Similarly, repeated exposure to MDMA, which acts partially through interactions with the serotonin, dopamine, and norepinephrine transporters, may alter sensitivity to DOI.</s><s>Although one early paper suggested no lasting effect of MDMA administration, <ref type="bibr" target="#b123">[124]</ref> a more recent report found that repeated MDMA treatment resulted in an enhanced sensitivity to DOI at a higher (3.0 mg/kg) but not a lower dose (0.5 mg/kg). <ref type="bibr" target="#b65">[66]</ref></s><s>ministration of quipazine, a mixed 5-HT 2 /5-HT 3 agonist results in a robust HTR in both mice and rats. <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b124">125,</ref><ref type="bibr" target="#b125">126]</ref></s><s>Co-administration of the 5-HT 3 receptor antagonist, ondansetron, does not substantially alter the DOI-elicited or quipazine-elicited HTR; <ref type="bibr" target="#b119">[120]</ref> we recently replicated this finding in our lab using C57Bl/6J mice (unpublished observations).</s><s>These data suggest that the 5-HT 3 receptor may not alter 5-HT 2 receptor function.</s><s>It is worth noting that some early studies suggested that quipazine was hallucinogenic in man, <ref type="bibr" target="#b126">[127]</ref> and a recent case report noted that quipazine produced a full hallucinogenic response when it was administered with a 5-HT 3 receptor antagonist, presumably to prevent nausea/vomiting associated with 5-HT 3 receptor activation. <ref type="bibr" target="#b14">[15]</ref></s><s>e 5-HT 7 receptor has been generating increasing interest as a potential target for drug development for the treatment of psychiatric disorders, including schizophrenia. <ref type="bibr" target="#b127">[128,</ref><ref type="bibr" target="#b128">129]</ref></s><s>To our knowledge, no selective 5-HT 7 compound has been tested in the DOI-induced HTR procedure, although all antipsychotic compounds are active in this model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Glutamate</head><p><s>There has been considerable interest in the role of glutamatergic systems in the DOI-elicited HTR.</s><s>Much of this interest stems from the putative involvement of 5-HT 2 receptors and glutamatergic systems in schizophrenia, <ref type="bibr" target="#b129">[130]</ref> and that the DOI-elicited HTR may be relevant as a model of schizophrenia.</s><s>To this end, numerous studies have examined pharmacological manipulations of both the ionotropic NMDA and AMPA receptors, and the metabotropic mGluR receptor systems.</s><s>For example, antagonism of the NMDA receptor by MK801 or ketamine, <ref type="bibr" target="#b130">[131]</ref><ref type="bibr" target="#b131">[132]</ref><ref type="bibr" target="#b132">[133]</ref> or antagonism of mGluR 2/3 autoreceptors by LY341495 <ref type="bibr" target="#b74">[75,</ref><ref type="bibr" target="#b133">134]</ref> consistently increase prefrontal cortical levels of glutamate and enhance the effects of DOI, indicated by increased HTRs elicited by a particular dose or shifts in the DOI dose-response curve to the left and upwards.</s></p><p><s>An equally compelling story has emerged regarding glutamatergic interventions that block the effects of DOI.</s><s>Activation of mGluR 2/3 autoreceptors with LY379268 and LY354740, which presumably leads to decreased extracellular levels of glutamate, decreased sensitivity to DOI. <ref type="bibr" target="#b74">[75,</ref><ref type="bibr" target="#b133">134]</ref> Similarly, administration of the glutamate release inhibitor riluzole or the glutamate analog theanine (which functions as a competitive antagonist) reduces DOIinduced HTRs. <ref type="bibr" target="#b134">[135]</ref></s><s>Recent studies have demonstrated that selective AMPA glutamate antagonists, such as GYKI52466, LY203558, and NBWX, attenuate DOI-induced HTRs. <ref type="bibr" target="#b130">[131,</ref><ref type="bibr" target="#b134">135]</ref></s><s>To complicate matters, it was recently demonstrated that the mGluR 2receptor knockout mice are insensitive to HTR-inducing effects of DOI (and LSD). <ref type="bibr" target="#b135">[136]</ref></s><s>lthough the neuropharmacological mechanisms underlying all of these interactions are not delineated, these data suggest a prominent role for glutamate receptor systems in the behavioural effects of DOI, and a strong interaction between glutamatergic and 5-HT 2 receptor systems.</s><s>Notably, it was recently discovered that 5-HT 2A and mGluR 2 receptors form heteromeric complexes that have unique signalling properties. <ref type="bibr" target="#b136">[137]</ref></s><s>BA Several allosteric modulators of the GABA A receptor have been examined for their influence on the DOI HTR.</s><s>Both the high efficacy benzodiazepine agonist diazepam and the inverse agonist flumazenil appear to have no influence on DOI-elicited HTRs, <ref type="bibr" target="#b66">[67,</ref><ref type="bibr" target="#b85">86,</ref><ref type="bibr" target="#b119">120,</ref><ref type="bibr" target="#b137">138]</ref> while the partial inverse agonist Ro154513 attenuates the DOI-induced HTR.</s><s><ref type="bibr" target="#b66">[67,</ref><ref type="bibr" target="#b137">138]</ref> Furthermore, the direct GABA A agonist bicuculline attenuates DOI-induced head twitches.</s><s><ref type="bibr" target="#b137">[138]</ref> More comprehensive studies directly comparing a range of compounds with various pharmacological actions at this receptor will help elucidate the potential modulatory role of GABA A receptors.</s><s>A single paper has examined the role of metabotropic GABA B receptors in DOI's behavioural effects.</s><s><ref type="bibr" target="#b138">[139]</ref> These authors demonstrated that both an agonist, CGP44532, and a positive allosteric modulator, GS39783, attenuated DOI-induced HTRs, which was reversed by two antagonists, CGP51176 and CGP36742, that had no effect on their own.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dopamine</head><p><s>Given the potential relevance of the behavioural effects of DOI as a model of schizophrenia, a number of studies have examined the influence of typical, dopamine D 2 antagonist, antipsychotic compounds on the HTR.</s><s>For example, haloperidol, chlorpromazine, and pimozide inhibit the HTR elicited by DOI. <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b67">68,</ref><ref type="bibr" target="#b71">72,</ref><ref type="bibr" target="#b119">120,</ref><ref type="bibr" target="#b139">140,</ref><ref type="bibr" target="#b140">141]</ref></s><s>Similarly, chronic administration of haloperidol results in a decreased sensitivity to DOI. <ref type="bibr" target="#b139">[140]</ref> Although they possess excellent affinity for D 2 receptors, these compounds are also 5-HT 2A receptor antagonists. <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b141">142]</ref></s><s>The more selective D 2 receptor antagonists, raclopride and sulpiride, show inconsistent effects or do not affect the DOI-elicited HTR. <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b71">72,</ref><ref type="bibr" target="#b140">141]</ref></s><s>The dopamine D 1 receptor antagonists, SCH23390 and SCH39166, which also have affinity for some serotonin receptors, inhibit DOI's behavioural effects; <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b140">141]</ref> these findings are consistent with observations that the D 1 receptor modulates glutamate and serotonin interactions in the prefrontal cortex. <ref type="bibr" target="#b142">[143]</ref></s><s>ocaine, a drug which blocks the reup-take of dopamine, 5-HT, and norepinephrine, attenuates DOI-elicited HTRs. <ref type="bibr" target="#b70">[71,</ref><ref type="bibr" target="#b143">144,</ref><ref type="bibr" target="#b144">145]</ref></s><s>Although many of cocaine's behavioural effects have been attributed to activity at the dopamine transporter, Darmani et al. have demonstrated repeatedly that attenuation of the HTR by cocaine can be reversed by administration of the 5-HT 1A antagonist, alprenolol, or the non-selective α 2 -adrenergic receptor antagonist, yohimbine, suggesting that cocaine's actions are mediated indirectly by increases in 5-HT 1A and α 2 -adrenergic activity. <ref type="bibr" target="#b70">[71,</ref><ref type="bibr" target="#b143">144,</ref><ref type="bibr" target="#b144">145]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cannabinoids</head><p><s><ref type="bibr" target="#b147">[148]</ref> Although SR141716A has no affinity for 5-HT receptors, <ref type="bibr" target="#b148">[149]</ref> it is of interest is that the 5-HT 2A/2C antagonist SR46349B potently reversed the effects of SR141716A, suggesting that activation of 5-HT 2 receptors may be related to the behavioural effects of SR141716A. <ref type="bibr" target="#b146">[147]</ref></s><s>Pretreatment with all CB1 agonists tested thus far, i.e.</s><s>THC (Δ9 and Δ8), anandamide, HU210, CP55940, and WIN55212 inhibit DOI's behavioural effects. <ref type="bibr" target="#b145">[146,</ref><ref type="bibr" target="#b149">150]</ref></s><s>Similarly, indirect cannabinoid agonists such as the anandamide transporter inhibitor AM404 and the FAAH inhibitor URB597, inhibit the HTR elicited by DOI. <ref type="bibr" target="#b134">[135]</ref></s><s>These data suggest close interactions between 5-HT 2 and cannabinoid receptors in vivo, which recent studies support. <ref type="bibr" target="#b150">[151,</ref><ref type="bibr" target="#b151">152]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acetylcholine</head><p><s>Acute and chronic administration of nicotine (direct agonist) and donepezil (acetylcholinesterase inhibitor; indirect agonist), two common drugs used in the treatment of Tourette's Syndrome, attenuate DOI-elicited HTRs.</s><s>Based on these findings, it has been suggested that the DOI-elicited HTR may be useful as a model of Tourette's Syndrome. <ref type="bibr" target="#b139">[140,</ref><ref type="bibr" target="#b152">153,</ref><ref type="bibr" target="#b153">154]</ref></s><s>The neurobiological mechanisms underlying these interactions are unknown, however, chronic administration of nicotine and donepezil results in decreased cortical 5-HT 2A receptor density. <ref type="bibr" target="#b139">[140]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Norepinephrine</head><p><s>]<ref type="bibr" target="#b156">[157]</ref><ref type="bibr" target="#b157">[158]</ref> Fewer studies have examined the role of norepinephrine in regulating the DOI-induced HTR; however, it was demonstrated that prazosin, an α 1/2 adrenergic receptor antagonist, completely blocks the DOI-elicited HTR. <ref type="bibr" target="#b140">[141]</ref></s><s>In this study, behavioural potency of 9 compounds (including prazosine) was significantly correlated with binding at 5-HT 2A and α 1 adrenergic receptors.</s><s>The finding that DOI itself has appreciable affinity for α 2 receptors <ref type="bibr" target="#b22">[23]</ref> suggests that DOI may directly affect the norepinephrine system, which may contribute to the behavioural effects of DOI.</s><s>We are currently investigating this possibility.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adenosine</head><p><s>One comprehensive paper has demonstrated a role for adenosine systems. <ref type="bibr" target="#b158">[159]</ref></s><s>Adenosine receptors are expressed in practically all neural systems in the brain, and their activation generally suppresses neural activity.</s><s>For example, activation of adenosine A1 receptors in the cortex reduces glutamate release. <ref type="bibr" target="#b159">[160]</ref></s><s>Thus, it follows that the adenosine A1 agonist, N <ref type="bibr" target="#b5">6</ref> cyclohexyladenosine, attenuates the DOI-elicited HTR, an effect that is reversed by the adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine. <ref type="bibr" target="#b158">[159]</ref></s><s>Of interest, the antagonist administered in combination with DOI enhances the HTR suggesting either that there is some basal level of adenosine receptor stimulation that modulates 5-HT 2A receptor activity or that the drug is non-selective for adenosine A 1 receptors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other systems</head><p><s>The mu opioid agonists, morphine and buprenorphine, and various atypical opiates, for example, tramadol and levorphanol, can attenuate the DOI-induced HTR in a naloxonereversible manner; <ref type="bibr" target="#b62">[63,</ref><ref type="bibr" target="#b160">161]</ref> for an exception see Wettstein et al. <ref type="bibr" target="#b119">[120]</ref> The neuropeptide, galanin, was demonstrated to attenuate DOI-elicited HTRs, and completely blocked HTRs elicited by DOB and mescaline. <ref type="bibr" target="#b161">[162,</ref><ref type="bibr" target="#b162">163]</ref></s><s>66]</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p><s>Taken together, the data described above suggest a number of neurotransmitter systems can alter behavioural effects elicited by the relatively selective 5-HT 2 agonist, DOI, and highlight the wide-ranging and complex interactions associated with 5-HT 2 receptors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neural and cellular systems underlying the psychoactive effects of DOI Neural systems</head><p><s>McKenna et al. <ref type="bibr" target="#b15">[16]</ref> first showed the distribution of DOI binding sites in rat brain using [ <ref type="bibr" target="#b124">[125]</ref> I]-(-)-DOI; the highest density of binding sites were observed in the cortex, claustrum, and olfactory bulb.</s><s>Although the entire spectrum of psychedelic effects are likely the result of emergent outputs from communication between several neural systems, <ref type="bibr" target="#b166">[167,</ref><ref type="bibr" target="#b167">168]</ref> several studies employing pharmacological, physiological, molecular, imaging, and/or genetic tools, have provided converging evidence that the cortex is the most primary site of action of the psychedelic effects of classical hallucinogens in man (e.g.</s><s>psilocybin <ref type="bibr" target="#b166">[167,</ref><ref type="bibr" target="#b168">169]</ref> ), their drug discrimination stimulus effects in rats (e.g.</s><s>LSD <ref type="bibr" target="#b114">[115]</ref> ), and their head-twitch-inducing effects in rats and mice (e.g.</s><s>DOI <ref type="bibr">[94,</ref><ref type="bibr" target="#b106">107]</ref> ).</s><s>Regarding DOI specifically, there are no studies (of which we are aware) aimed at deciphering its neuroanatomical site of psychedelic action in man, likely relating to its long duration of action, i.e. 16-30 h, <ref type="bibr" target="#b5">[6]</ref> which would render clinical studies arduous to perform.</s><s>However, based on results from similar classical hallucinogens, the cortex is probably the primary site mediating its hallucinogenic effects in man.</s></p><p><s>Whether or not there is a specific cortical region(s) that is necessary for producing the psychedelic effects of classical hallucinogens is not fully elucidated, but data point to the cingu-late gyri, a neural system located dorsomedially in the cortex, and implicated in decision making, emotion, and pain processing. <ref type="bibr" target="#b169">[170]</ref></s><s>Psilocybin increases cerebral metabolic activity in the cingulate cortex in humans. <ref type="bibr" target="#b168">[169]</ref></s><s>Also, direct injections of d-LSD into the cingulate cortex of rats dose-dependently substituted for systemic injections of d-LSD in a drug discrimination task; injections outside this region, including rostrally, into the orbital cortex, did not substitute. <ref type="bibr" target="#b114">[115]</ref></s><s>Also, direct injections of DOI into the cingulate cortex dosedependently induced the HTR in rats. <ref type="bibr" target="#b106">[107]</ref></s><s>Moreover, restoration of expression of 5-HT 2A receptors solely in the cortex, including the cingulate cortex, of 5-HT 2A receptor knockout mice restored the ability of DOI to induce an HTR. <ref type="bibr">[94]</ref></s><s>llular systems: neurophysiology and neurochemistry Many more studies have examined the cellular, both physiological and genetic, effects of DOI.</s><s><ref type="bibr" target="#b172">[173]</ref><ref type="bibr" target="#b173">[174]</ref> 5-HT 2A receptors are most abundant on glutamatergic pyramidal neurons and GABAergic interneurons of the prefrontal cortex, where they robustly stud somatodendritic regions of layer V. <ref type="bibr" target="#b170">[171,</ref><ref type="bibr" target="#b171">172,</ref><ref type="bibr" target="#b174">[175]</ref><ref type="bibr" target="#b175">[176]</ref><ref type="bibr" target="#b176">[177]</ref><ref type="bibr" target="#b177">[178]</ref> Thus, much focus, regarding the cellular effects of DOI, has been on layer V of the cortex.</s><s>5-HT 2 receptor activation by DOI significantly alters glutamate release and glutamatergic pyramidal neuron activity in the medial prefrontal cortex (layer V, predominantly), an effect that recent studies show is likely post-synaptically mediated and intrinsic to cortical-cortical circuits.</s><s>[179,180] Results from both in vitro and in vivo studies in rats show that DOI increases spontaneous and evoked excitatory currents in layer V pyramidal cells (EPSCs), <ref type="bibr" target="#b180">[181,</ref><ref type="bibr" target="#b181">182]</ref> increases the firing rate of a majority of neurons, but also decreases the firing rate of a significant number of layer V cells <ref type="bibr" target="#b182">[183]</ref> and also unidentified medial prefrontal cortex cells, <ref type="bibr" target="#b183">[184]</ref> reduces low-frequency oscillations, and desynchronizes pyramidal cell discharge from active phases of slow oscillations of medial prefrontal cortex cells. <ref type="bibr" target="#b178">[179]</ref></s><s>The majority of these effects are abolished by M100907 or other 5-HT 2A antagonists, suggesting they are 5-HT 2A receptor-mediated.</s><s>However, for full disclosure, it should be noted that Puig et al. <ref type="bibr" target="#b182">[183]</ref> reported that the DOI-induced increase in firing rate was not reversed by systemic injections of M100907 (up to 0.5 mg/kg) in 33% (3/9) of the cells examined.</s><s>Furthermore, the excitatory effects of the 5-HT 2 agonist, am-5-HT, were mostly, yet not completely absent in cortical pyramidal cells from 5-HT 2A receptor knockout mice; indeed 23% (9/39) of cells examined from these mice showed measurable am-5-HT-induced increases in EPSCs that were subsequently blocked by the selective 5-HT 2C antagonist, SB242084. <ref type="bibr" target="#b179">[180]</ref></s><s>Also, although the increase in EPSCs by am-5-HT was completely abolished by M100907 in pyramidal cells from wild-type mice, the concentration used, 300 nM, [180] was approximately 6-fold higher than its Ki for 5-HT 2C (human, INI isoform) receptors. <ref type="bibr" target="#b2">[3]</ref></s><s>Thus, the direct neurophysiological effects of DOI in pyramidal cells of layer V of the cortex likely involve activation of both 5-HT 2A and 5-HT 2C receptors, and subsequent increases in local glutamate release.</s><s>]<ref type="bibr" target="#b186">[187]</ref><ref type="bibr" target="#b187">[188]</ref><ref type="bibr" target="#b188">[189]</ref> These effects of DOI, however, are likely secondary to activation of 5-HT 2 receptors on cortical pyramidal neurons, which send efferent projections to regulate neurotransmitter release from subcortical 5-HT, dopamine, and acetylcholine-producing neurons.</s><s>]<ref type="bibr" target="#b188">[189]</ref> Moreover, the DOI-induced increase in cortical dopamine release is absent in 5-HT 2A receptor, but not 5-HT 2C receptor knockout mice, suggesting this effect is 5-HT 2A mediated. <ref type="bibr" target="#b189">[190]</ref></s><s>Notably, 5-HT 2C receptor knockout mice show, relative to wild-type mice, increased firing of dopaminergic substantia nigra neurons. <ref type="bibr" target="#b190">[191]</ref></s><s>Whether this effect is related to 5-HT 2C receptors on cells in the substantia nigra or is an indirect effect is unknown to us.</s><s>Similarly, the increases in 5-HT in the medial prefrontal cortex in rats produced by direct DOI injections were blocked by co-application of the glutamate AMPA receptor antagonist, NBQX, but not SB242084, suggesting the DOI-induced 5-HT release in the cortex is mediated by 5-HT 2A receptors on pyramidal neurons; though local 5-HT 1A and alpha-adrenergic receptors were also involved. <ref type="bibr" target="#b37">[38]</ref></s><s>llular systems: intracellular proteins At the molecular level, DOI causes strong expression, in cortical layer V neurons, of the immediate early gene c-fos, an effect blocked by pretreatment with M100907, but not by SB206553 (up to 6 mg/kg, <ref type="bibr" target="#b191">[192]</ref> ), and not observed in 5-HT 2A knockout mice, <ref type="bibr" target="#b192">[193]</ref> suggesting it is specifically 5-HT 2A receptor mediated. <ref type="bibr" target="#b191">[192]</ref></s><s>The induction of c-Fos protein in layer V by DOI likely does not, however, mediate its HTR-inducing effects, as the non-HTR-producing 5-HT 2A agonist, lisuride, also induces c-Fos expression in the cortex. <ref type="bibr">[94]</ref></s><s>DOI, but not lisuride, induced cortical expression of egr-1 and egr-2. <ref type="bibr">[94]</ref></s><s>Though these genetic markers, also, do not underlie DOI's HTR-inducing effects, as their maximal induction was not observed until an hour after injection of DOI, whereas the HTR to DOI was observed within minutes of injection; furthermore, mice lacking egr-1 show a normal response to DOI. <ref type="bibr" target="#b193">[194]</ref> 5-HT 2 receptors share a common signalling pathway involving coupling with Gq/11 proteins that leads to activation of phospholipase Cβ, production of diacylglycerol, release of Ca ++ from intracellular stores, and modulation of activity of several other intracellular proteins, including PKC and extracellular signal-regulated kinase (ERK). <ref type="bibr" target="#b194">[195]</ref></s><s>Mice lacking the Gq protein show a reduction in number, but not an elimination of HTRs induced by DOI. <ref type="bibr" target="#b195">[196]</ref></s><s>Although alterations in density of 5-HT 2 receptors are not associated with alterations in the level of Gq proteins, <ref type="bibr" target="#b196">[197,</ref><ref type="bibr" target="#b197">198]</ref> to our knowledge the converse is not known.</s><s>Nevertheless, these data suggest that G proteins, other than Gq, that interact with 5-HT 2 receptors, including Gi and G12/13 (5-HT 2C receptors, <ref type="bibr" target="#b198">[199,</ref><ref type="bibr" target="#b199">200]</ref> ) may also contribute to its HTR-producing effect.</s><s>Also notable, DOI-induced c-Fos expression in the medial prefrontal cortex was completely abolished in Gq knockout mice, <ref type="bibr" target="#b195">[196]</ref> providing further evidence that c-Fos is not a critical molecular component of the DOI HTR.</s></p><p><s>Other intracellular contributors to the HTR induced by DOI include PKCγ.</s><s>Mice lacking the neuronal specific, PKCγ, show enhanced DOI-induced phospholipase C activation and increased number of DOI-induced HTRs, suggesting a suppressive effect of PKCγ on DOImediated intracellular functions. <ref type="bibr" target="#b200">[201]</ref></s><s>Importantly PKCγ knockout mice do not show alterations in brain 5-HT 2A receptor density. <ref type="bibr" target="#b200">[201]</ref></s><s>veral new studies have begun to elucidate the G-protein independent β-arrestin pathway, which is modulated by 5-HT 2A receptors.</s><s>Recently it was shown that the DOI-induced HTR is unaffected by knockout of β-arrestin2 in mice, yet the HTR from the hallucinogens Nmethyl-5-HT and 5-MeO-DMT is significantly enhanced in these mice; on the other hand, the HTR induced by the non-hallucinogenic compound, 5-HTP, is severely diminished, relative to wild-type littermates. <ref type="bibr" target="#b201">[202,</ref><ref type="bibr" target="#b202">203]</ref></s><s>Moreover, the HTR induced by all of these compounds is blocked by M100907, suggesting unique 5-HT 2 -mediated signalling pathways induced by DOI and other HTR producing compounds <ref type="bibr" target="#b201">[202,</ref><ref type="bibr" target="#b202">203]</ref> that may be activated by stabilization of agonist-specific receptor conformations.</s><s>Schmid et al. <ref type="bibr" target="#b201">[202]</ref> and Abbas et al. <ref type="bibr" target="#b203">[204]</ref> showed that DOI induces phosphorylation of ERK in cortical cells.</s><s>This event, however, does not seem to be necessary for the discriminative stimulus effects of DOI, as systemic injections of SL327 that attenuated cerebral ERK phosphorylation, did not lessen the ability of mice to discriminate DOI from vehicle (Sanders-Bush et al., unpublished observations).</s><s>Whether blockade of cortical ERK phosphorylation affects the DOI-induced HTR has not been reported to our knowledge.</s></p><p><s>Recent studies have described a substantial function of scaffolding and other 5-HT 2 interacting proteins in the cellular and behavioural effects of DOI.</s><s>For example, mice lacking the receptor-scaffolding protein, postsynaptic density protein of 95 kDa (PSD-95), traditionally considered a glutamatergic scaffolding protein, show a reduction, yet not abolishment of the HTR induced by DOI. <ref type="bibr" target="#b203">[204]</ref></s><s>PSD-95 knockout mice showed decreases in brain 5-HT 2A and 5-HT 2C receptor expression (yet not 5-HT 1A receptors), and 5-HT 2C receptor function, but did not show reductions in 5-HT 2A or 5-HT 2C mRNA levels.</s><s>Furthermore, 5-HT 2A receptor trafficking to the cortical dendritic compartment in PSD-95 knockout mice was reduced.</s><s>These data suggested the effect of PSD-95 elimination on the DOI HTR was mediated by reduced 5-HT 2 receptor expression in the cortex. <ref type="bibr" target="#b203">[204]</ref></s><s>terestingly, other studies have shown that DOI induces region-specific induction of BDNF mRNA, including induction in layer V of the rat cortex, <ref type="bibr" target="#b204">[205,</ref><ref type="bibr" target="#b205">206]</ref> which can be suppressed by the mGlu2/3 agonist, LY354740, and enhanced by the mGlu2/3 antagonist LY341495. <ref type="bibr" target="#b205">[206]</ref></s><s>lso, BDNF induces transport of PSD95 to cortical dendritic spines. <ref type="bibr" target="#b207">[208]</ref></s><s>In BDNF knockout mice, 5-HT 2A receptor binding sites were significantly decreased in the cortex compared to wild-type mice; the HTR to DOI, nevertheless, was not altered in BDNF knockout mice (though the ear-scratch response to DOI was significantly different <ref type="bibr" target="#b207">[208]</ref> ).</s><s>Finally, there are several other 5-HT 2A and 5-HT 2C -interacting proteins that could regulate the effects of DOI, including PDZ domain-containing proteins, such as Mupp-1, and non-PDZ-domaincontaining proteins, such as Arf-1, caveolin, RSK2, and MAPs. <ref type="bibr" target="#b208">[209]</ref></s><s>veats: resolution of conflicting data</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Species and strain differences</head><p><s>Behavioural differences-There are many discrepancies in the DOI HTR literature that clearly appear related to the animal subject tested.</s><s>For example, as shown in Table <ref type="table">1</ref>, mice and rats exhibit widely varying numbers of DOI-elicited HTRs within a defined time period, with mice typically showing a greater number of HTRs than rats.</s><s>There are also large differences, up to 10-fold, between strains within a given species, and even across sub-strains, i.e.</s><s>C57Bl/6J mice (Jackson Laboratories) <ref type="bibr" target="#b64">[65,</ref><ref type="bibr">76]</ref> compared to C57Bl/6 N mice (Harlan Laboratories), <ref type="bibr" target="#b73">[74]</ref> as shown in Table <ref type="table">1</ref>.</s><s>The time between injection of DOI and the start of HTR counting, however, was notably different, i.e. 10 min <ref type="bibr" target="#b64">[65,</ref><ref type="bibr">76]</ref> compared to 0 min; <ref type="bibr" target="#b73">[74]</ref> we have observed that the frequency of HTRs after peripheral injections of DOI increases within the first 2 min (Figure <ref type="figure" target="#fig_1">2</ref>), similar to Darmani et al. <ref type="bibr">[56]</ref> Thus, these differences may appear more striking than they are.</s><s>Experimenter variability does not likely account for most of the variance observed, as reports from several experiments directly comparing mouse strains show significant differences in HTR following DOI injections.</s></p><p><s>Different receptor densities-A recent report noted that mice and rats have different ratios of 5-HT 2A/2C receptor binding site densities in the brain, with the former showing a greater ratio than the latter, i.e. relatively more 5-HT 2A receptors than 5-HT 2C receptors in the mouse brain. <ref type="bibr" target="#b73">[74]</ref></s><s>It could be argued that these observations explain some of the variability between DOI HTRs in rats and mice.</s><s>Some studies have suggested that activation of 5-HT 2C receptors inhibits 5-HT 2A receptor function induced by DOI (discussed above in the section on 5-HT 2C and below in the section, "Dosing issues: problem of nonselectivity").</s><s>Following this logic, because there are fewer 5-HT 2C receptors potentially suppressing 5-HT 2A receptor activity in mice relative to rats, mice exhibit a greater number of HTRs elicited by DOI.</s><s>Neither 5-HT 2A nor 5-HT 2C receptor binding site densities, however, explained the differences in DOI-elicited HTRs between C57Bl/6J and DBA/2J mice.</s><s>DBA/2J mice exhibited an almost 2-fold greater frequency in DOI-induced HTRs relative to C57Bl/6J mice, yet had approximately equivalent 5-HT 2A and 5-HT 2C receptor binding site densities in brain areas examined; <ref type="bibr" target="#b64">[65]</ref> though not reaching statistical significance, a closer look at the data, however, suggest that 5-HT 2A receptors in the posterior striatum may be more dense in DBA/2J than C57Bl/6J mice.</s><s>As suggested previously, <ref type="bibr" target="#b10">[11]</ref> autoradiography techniques are relatively poor for deciphering subtle, but potentially important, differences in receptor binding site density.</s></p><p><s>The fact that there are substantially greater numbers of 5-HT 2A receptors, compared to 5-HT 2B and 5-HT 2C receptors, expressed in the brains of most species, is pertinent when considering the relative contribution of these receptors to the effects of DOI.</s><s>Namely, 5-HT 2A receptors may have a greater, and more easily detectable, role in DOI's effects simply because they exist in greater numbers and therefore have greater control over neurophysiological processes in regions where the three receptors are co-expressed.</s><s>Thus, the potential 5-HT 2B and 5-HT 2C receptor-mediated functions in hallucinogen HTR studies and drug discrimination tasks may be masked by 5-HT 2A receptors when all three receptors are activated simultaneously, as occurs with DOI.</s><s>Considering a hypothetical example, if a mouse model were created that over-expressed 5-HT 2A receptors, and another 5-HT 2B receptors, and another 5-HT 2C receptors, and each was trained to discriminate DOI from saline, it seems logical that 5-HT 2A selective antagonists would more readily block the discriminative cue in 5-HT 2A over-expressing mice (similar to wild-type mice), but would be less effective in blocking the cue in 5-HT 2B over-expressing mice, and likewise for all other iterations.</s><s>Finally, although the translated DNA sequences for 5-HT 2 receptors are ~98% identical between rats and mice, and ~90% identical between mice and humans, <ref type="bibr" target="#b209">[210]</ref> it is not currently known whether selective 5-HT 2 ligands have the same affinities and functions at both mouse and rat 5-HT 2 receptors (discussed below).</s><s>It is well known that changing even a single residue in a critical region of the transmembrane domain (where most ligands bind) of a G protein-coupled receptor can substantially alter ligand affinity and function (e.g. for 5-HT 2A and 5-HT 2C receptors <ref type="bibr" target="#b210">[211,</ref><ref type="bibr" target="#b211">212]</ref> ).</s><s>Though these regions of the 5-HT 2 receptors tend to be conserved across species, potentially other, unidentified regions of the receptors that differ between species may be important in determining a given ligand's affinity for and function at these receptors.</s><s>Notably, the differences between rodent and human 5-HT 2A receptors result in considerable differences in the pharmacology of N-1 substituted tryptamines and ergolines. <ref type="bibr" target="#b208">[209,</ref><ref type="bibr" target="#b212">213,</ref><ref type="bibr" target="#b213">214]</ref></s><s>sing issues: problem of non-selectivity-The issue of drug dose is a critical one in behavioural and neuropharmacological studies, and is regularly overlooked, as it is sometimes presumed that when a compound is described as 'selective', it means 'specific'.</s><s>5-HT 2 receptors share approximately 80% sequence homology in their transmembrane domains, which makes development of very specific 5-HT 2 subtype-selective compounds a tedious endeavour, and thus determination of the 5-HT 2 receptor subtypes involved in the behavioural effects of DOI also an ongoing challenge.</s><s>Although the antagonists/inverse agonists, M100907, SB206553, and SB242084, which for human receptors, show at least 100-fold selectivity for 5-HT 2A , 5-HT 2B/2C , and 5-HT 2C receptors, respectively, were a practical boon for the field, their relative affinities for 5-HT 2 receptors from a range of laboratory species have not yet been reported.</s><s>In addition, it is important to keep in mind that although M100907, for example, has extremely high affinity (0.1 nM K i ) for the human 5-HT 2A receptor, its affinity for human 5-HT 2C receptors (~50 nM K i ) is not dismissible.</s></p><p><s>Recent studies suggest that the activities of these newer and commonly used compounds may differ at mouse and rat 5-HT 2 receptors.</s><s>SB206553, for example, dose-dependently, but partially, attenuated the stimulus effects of 2.5 mg/kg (±)-DOI in a drug discrimination paradigm in C57Bl/6J mice, <ref type="bibr" target="#b110">[111]</ref> findings that did not extend to Sprague-Dawley rats, despite using a lower dose of DOI (0.5 mg/kg) and much higher doses of SB206553. <ref type="bibr" target="#b10">[11]</ref></s><s>100907 completely blocked the DOI stimulus effect in both studies, though a 0.25 mg/kg dose was required for maximal effect in mice, whereas a 0.02 mg/kg dose produced maximal blockade in rats. <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b110">111]</ref></s><s>recent neuroendocrine study in Sprague-Dawley rats that included a full dose-response curve showed that SB242084 up to 10 mg/kg did not block corticosterone increases caused by 0.3 mg/kg DOI, yet M100907 completely blocked corticosterone increases caused by DOI with an ED50 value of 0.0035 mg/kg, <ref type="bibr" target="#b214">[215]</ref> suggesting this effect is 5-HT 2A -mediated.</s><s>However, these data should not suggest that all of the behavioral effects of M100907 are solely due to antagonism of 5-HT 2A receptors.</s><s>For example, in a drug discrimination study using Wistar rats, although it was reported that neither SB206553, nor SB242084 at doses up to 10 mg/kg significantly generalized to 0.16 mg/kg M100907, there was approximately 40% generalization with 0.16 mg/kg SB206553 and 20% generalization with 2.5 mg/kg SB242084, yet 0% generalization with the 5-HT 2B selective antagonist SB204741.</s><s><ref type="bibr" target="#b215">[216]</ref> These data illustrate that the stimulus cue elicited by 0.16 mg/kg M100907 may involve some blockade of 5-HT 2C receptors, or may involve other unidentified receptors targeted by these compounds.</s></p><p><s>As another example, in Wistar rats trained to discriminate the selective 5-HT 2C receptor agonist, Ro 60-0175 (2.5 mg/kg), from saline, SB 206553 (0.63 mg/kg) was 100%, SB 242084 (0.63 mg/kg) was 80%, and M100907 (0.16 mg/kg) was 40% effective at blocking the discriminative cue. <ref type="bibr" target="#b216">[217]</ref></s><s>It must be emphasized that although touted as a highly selective and potent 5-HT 2C agonist, Ro 60-0175 also likely causes behavioural effects mediated by receptors other than 5-HT 2C , such as 5-HT 2A and 5-HT 2B receptors.</s><s>Comparing affinities for each of the human 5-HT 2 receptors, Ro 60-0175 has highest affinity for 5-HT 2B receptors (the 5-HT 2C-VSV isoform was tested), <ref type="bibr" target="#b33">[34]</ref> and has greatest potency for activating 5-HT 2B receptors. <ref type="bibr" target="#b18">[19]</ref></s><s>Moreover, the neuroendocrine stimulating effects (including release of corticosterone) of Ro 60-0175 in Sprague-Dawley rats, which occurred above 2.5 mg/kg, were not blocked by pretreatment with SB242084 (at doses up to 5 mg/kg) or M100907 (0.01 mg/kg). <ref type="bibr" target="#b217">[218]</ref></s><s>Taken together, these data illustrate an often ignored point that 'selective' does not translate to 'specific'.</s><s>Thus, a titration of doses for any given 5-HT 2A, 2B, or 2C selective compound is necessary to begin to determine specific 5-HT 2 receptor subtypes that may be involved in a particular behavioural outcome.</s><s>Also, many compounds, such as SB206553, <ref type="bibr" target="#b218">[219]</ref> have affinity for off-target receptors and other proteins that may play a role in their behavioural effects.</s></p><p><s>As discussed in a previous section (5-HT 2C ), similar dosing issues and discrepant findings are apparent using the DOI HTR model.</s><s>For example, although Ro 60-0175 at 2.5 mg/kg was an effective training dose in drug discrimination studies, <ref type="bibr" target="#b216">[217]</ref> caused significant neuroendocrine activation, <ref type="bibr" target="#b217">[218]</ref> and significant changes in release of cerebral dopamine <ref type="bibr" target="#b219">[220,</ref><ref type="bibr" target="#b220">221]</ref> in rats, 3.0 mg/kg was ineffective at attenuating the HTR induced by 1.0 mg/kg ( )-DOI; 10 mg/kg was required to attenuate the HTR in mice, and-even the highest dose tested, 30 mg/kg, was ineffective at abolishing the HTR in these mice. <ref type="bibr" target="#b72">[73]</ref></s><s>242084 up to 3 mg/kg does not block the HTR in Listar rats induced by 0.2 mg/kg (±)-DOI, <ref type="bibr" target="#b112">[113]</ref> yet blocks 50% of the HTRs induced by 1 mg/kg (±)-DOI in C57Bl/6J and DBA/ 2J mice; SB206553 at 0.3 and 3 mg/kg led to the same result, <ref type="bibr" target="#b64">[65]</ref> a finding (with C57Bl/6J mice) we recently confirmed at a different institution (unpublished observations).</s><s>Nevertheless, this general finding was not observed in Swiss NIH mice. <ref type="bibr" target="#b72">[73]</ref></s><s>One possibility for these discrepant findings is that 5-HT 2C antagonists, such as the 5-HT 2C/2B antagonist SB206553, block 5-HT 2A receptors in C57Bl/6J but not Swiss NIH mice.</s><s>EEDQ irreversible binding of 5-HT 2A receptors, however, was not attenuated by pretreating C57Bl/6J mice with 3 mg/kg SB206553, yet was by pretreatment with 0.25 mg/kg M100907, <ref type="bibr" target="#b64">[65]</ref> suggesting this is not the answer.</s></p><p><s>Finally, in Wistar rats, SB206553 at 1.8 mg/kg inhibited the HTR induced by the 5-HT 2/3 receptor agonist quipazine. <ref type="bibr" target="#b221">[222]</ref></s><s>Proteins other than 5-HT 2 receptors, including 5-HT 2 interacting proteins <ref type="bibr" target="#b203">[204,</ref><ref type="bibr" target="#b208">209]</ref> and perhaps enzymes, such as monoamine oxidase, are likely involved in regulating the HTR and may differ between species (as noted in studies aimed at deciphering the species differences in toxicity caused by MPTP injections <ref type="bibr" target="#b222">[223]</ref> ).</s><s>Obviously, dose is not the only issue here.</s></p><p><s>Several pharmacological studies have suggested there are different and often opposing neurochemical functions of 5-HT 2A and 5-HT 2C receptors; the most widely reproduced observation is that 5-HT 2A receptor activation increases, whereas 5-HT 2C receptor activation decreases dopamine release in cortex, dorsal striatum, and nucleus accumbens, <ref type="bibr" target="#b189">[190,</ref><ref type="bibr" target="#b219">220,</ref><ref type="bibr" target="#b220">221]</ref> which could suggest that DOI has auto-opposing (or auto-regulating) neurochemical effects.</s><s>Regarding 5-HT 2C receptor function, the 5-HT 2C agonist, Ro 60-0175 most effectively decreased dopamine release at concentrations at or above 2.5 mg/ kg. <ref type="bibr" target="#b219">[220,</ref><ref type="bibr" target="#b220">221]</ref></s><s>Although both 5-HT 2C receptor antagonists increased dopamine release, the effects of SB206553 (combined 5-HT 2B/2C antagonist) were more robust than SB242084, and the increase in dopamine release following SB206553, but not SB242084, injections in Sprague-Dawley rats were dose-dependent up to 10 mg/kg. <ref type="bibr" target="#b220">[221]</ref></s><s>This dose is notably very high, considering that 0.63 mg/kg SB206553 (and SB242084) is sufficient to block 100% (and 80%, respectively) of the Ro 60-0175 (2.5 mg/kg) discriminative cue in rats, <ref type="bibr" target="#b216">[217]</ref> and suggests that receptors in addition to 5-HT 2C receptors, including nicotinic acetylcholine receptors <ref type="bibr" target="#b218">[219]</ref> and 5-HT 2B receptors, may also be regulating the increases in dopamine release by SB206553.</s><s>Alternatively, the differences between SB206553 and SB242084 may relate to the observations that the former behaves as a 5-HT 2C receptor inverse agonist, while the latter behaves as a partial 5-HT 2C receptor agonist, able to attenuate inverse agonist functions of SB206553 (in vitro, recombinant receptors, isoform unspecified, in CHO cells, PLC function). <ref type="bibr" target="#b220">[221]</ref></s><s>These data suggest that constitutive activity of 5-HT 2C receptors may be as important as endogenous 5-HT induced activation of 5-HT 2C receptor for regulation of basal dopamine release.</s><s>DOI injections (2.5 mg/kg) increased dopamine release in the rat cortex, an effect not observed in 5-HT 2A receptor knockout mice, but preserved in 5-HT 2C receptor knockout mice. <ref type="bibr" target="#b189">[190]</ref></s><s>Curiously, DOI's effects on dopamine release were not potentiated in 5-HT 2C receptor knockout mice, <ref type="bibr" target="#b189">[190]</ref> and yet this group reported that increases in the concentration of DOI injected systemically (0, 1.25, 2.5, and 5 mg/kg) produced an inverted U-shaped dose-response curve for dopamine release, and suggested, though did not show, that increased activation of 5-HT 2C receptors by DOI mediated the descending part of the curve. <ref type="bibr" target="#b223">[224]</ref></s><s>I at 1 mg/kg, as noted previously, reliably induces a HTR that is blocked by 5-HT 2 antagonists, yet this dose was not sufficient to induce increases in acetylcholine in the rat hippocampus; 2 mg/kg was. <ref type="bibr" target="#b187">[188]</ref></s><s>Finally, also intriguing are results from neurophysiology studies of DOI.</s><s>In cortical cells, ex vivo, DOI at a concentration of 300 nM, well above its reported K i and EC50 values (in vitro) for 5-HT 2 receptors, <ref type="bibr" target="#b18">[19]</ref> had no effect on electrochemical activity; 1 mM was needed to alter activity, and 30 nM M100907 blocked the effects. <ref type="bibr" target="#b34">[35]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug-specific stabilization of receptor conformations</head><p><s>It is becoming increasingly clear that different ligands that bind to the same GPCR induce or stabilize unique receptor conformations, and furthermore, that the conformational changes may be different when receptors are expressed in different cell types. <ref type="bibr" target="#b224">[225]</ref></s><s>The stabilization of unique receptor conformations by different ligands positions the receptor to have selective interactions with G-protein subtypes or even with signalling proteins other than Gproteins (e.g.</s><s>β-arrestin); these unique interactions confer activation (or inactivation) of potentially several specific cellular signalling pathways, a phenomenon known as functional selectivity or biased agonism. <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b225">226]</ref></s><s>Thus, as described by Kenakin, <ref type="bibr" target="#b226">[227]</ref> G-protein coupled receptors are no longer viewed as 'on-off switches', but are more akin to 'microprocessors' regulated by interacting proteins and ligands that bind them.</s><s>Therefore, designation of a ligand simply by its efficacy as an agonist (partial or full), antagonist (competitive or non-competitive), or inverse agonist of a particular receptor, is not adequately informative without specifying the relative endpoint that is measured.</s><s>For example, a ligand at 5-HT 2A receptors could be a full agonist for the recombinant rat 5-HT 2A receptor-Gq-PLC-IP pathway plus a partial agonist for the 5-HT 2A -G12-PLD pathway when the receptor is expressed in Chinese hamster ovary cells.</s><s>When examined in the rat claustrum in vivo, however, the same ligand may show weak partial agonist activity for the 5-HT 2A receptor-Gq-PLC pathway, and no activity at the 5-HT 2A -G12-PLD pathway; thus the ligand may actually behave as an antagonist of endogenous serotonin.</s><s>Many of the conflicting data regarding DOI's behavioural pharmacology may be explained by unique functionally selective activity at several receptors, expressed in vivo, on different neural cells, on physically distinct parts of the cells, across species and strains.</s></p><p><s>Most 5-HT 2 receptor agonists that are hallucinogenic are partial agonists, with similar potencies and efficacies (for stimulation of PLC-IP and others) for 5-HT 2A and 5-HT 2C receptors.</s><s>So, why are other 5-HT 2A/2C agonists, such as the phenylpiperazine, mCPP, and the benzazapine, lorcaserin <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b227">[228]</ref><ref type="bibr" target="#b228">[229]</ref><ref type="bibr" target="#b229">[230]</ref> generally considered non-hallucinogenic?</s><s>That is, why don't these compounds produce psychedelic effects comparable to LSD?</s><s>Besides having notably poorer potency for activating either or both 5-HT 2A and 5-HT 2C receptors, another argument (discussed in detail previously) is that 5-HT 2C receptor activation suppresses (or alters) 5-HT 2A receptor function, and 5-HT 2 agonists lacking LSD-like effects are generally considered relatively more potent and efficacious 5-HT 2C receptor agonists compared to 5-HT 2A receptors.</s><s>This argument seems untenable, though, simply because hallucinogens that produce LSD-like effects are 5-HT 2C agonists; if 5-HT 2C receptors suppressed hallucinogenic effects, LSD wouldn't be hallucinogenic, a point lost in many discussions.</s><s>It should be noted, also, that several phenylpiperazines fully substituted for the mCPP stimulus in rats, yet LSD and (-)-DOM only partially substituted.</s><s>The efficacy of phenylpiperazines for stimulating 5-HT 2C receptor-linked PLC signalling, moreover, was not directly related to their stimulus generalization effects. <ref type="bibr" target="#b230">[231]</ref></s><s>Thus, these data suggest that the stimulus effects of phenylpiperazines are not mediated by the primary 5-HT 2C receptor signalling pathway.</s></p><p><s>Regardless, a more parsimonious explanation is that certain 5-HT 2 receptor-activating compounds, such as DOI and psilocin, cause specific conformations of 5-HT 2 receptors that lead to LSD-like psychedelic effects. <ref type="bibr">[94,</ref><ref type="bibr" target="#b231">232]</ref></s><s>Moreover, although the 5-HT 2 agonists mCPP, lorcaserin, and quipazine, are often considered 'non-hallucinogenic', they actually do produce perceptual, cognitive, and emotional changes that may be considered 'hallucinogenic'. <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b232">233,</ref><ref type="bibr" target="#b233">234]</ref></s><s>These effects, however, are generally not considered LSD-like.</s><s>Finally, it is noteworthy that novel, partial 5-HT 2A /D 2 receptor agonists also attenuate the DOI-elicited HTR. <ref type="bibr" target="#b234">[235,</ref><ref type="bibr">236]</ref></s><s>These observations provide further support for the idea that DOI potentially stabilizes a 5-HT 2A receptor conformation unique from other 5-HT 2A receptor agonists.</s><s>It would be interesting to know whether pre-treatment with LSD or DOM attenuates the DOI-induced HTR, as the outcome could potentially strengthen the argument for ligand-specific receptor conformations.</s><s>Molecular modelling and computational studies of different 5-HT 2A agonists docked in the 5-HT 2A receptor binding pocket would also help clarify this point.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animal models</head><p><s>Animal models of human behaviour or psychiatric disorders are typically used to mimic some aspect of the human condition.</s><s>As is true for all models it is imperative to clearly and explicitly identify the purpose of the model -what are you trying to 'model'?</s><s>The degree to which any particular animal model is useful can then be assessed through various forms of validity.</s><s>The purpose of a particular model can vary, and may include:</s></p><p><s>• mimicking an entire behavioural or psychiatric syndrome;</s></p><p><s>• modelling a particular behavioural phenomenon or psychiatric symptom, i.e. an endophenotype of a disease; and</s></p><p><s>• predicting the outcome a particular experimental intervention (e.g. an environmental, behavioural, pharmacological, or neurobiological manipulation).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Model validity</head><p><s>Although a wide variety of validity types have been described, one common categorization of validity for assessing a model of 'normal' or 'pathological' behaviour includes the following:</s></p><p><s>• Face validity refers to the phenomenological similarities between the behaviour of interest in the animal and the behaviour (pathological or not) of the 'real-world' human; that is, do the behaviours resemble each other on the 'face' of it.</s><s>This is not required for an animal model, and is oftentimes detrimental as it can imply inaccurately similar underlying mechanisms in the model and the human condition.</s></p><p><s>• Predictive validity refers to the ability of the model to predict something about the human condition; that is, does the outcome of testing in the animal model allow you to predict the response in humans?</s><s>This is the most important and desirable aspect of a model, and is oftentimes assessed by similar outcomes of neurobiological or pharmacological interventions in the animal model and humans.</s></p><p><s>• Etiological validity refers to situations in which the animal and the human condition are "caused" by the same mechanism; that is, the etiology of the behavioural or psychiatric phenomenon is identical.</s><s>Advances in the study of genetic vulnerability to various psychiatric disorders and our ability to manipulate the genetic makeup of animals are leading to increases in model development along these lines, although this presumes that we know the cause of a particular disorder (which is often not the case).</s></p><p><s>• Construct validity refers to the notion that the animal model is measuring what it was intended to measure; that is, there is close functional homology between the behavioural phenomena in the animal model and the human condition.</s><s>This requires a high degree of theoretical and/or conceptual understanding of the phenomena, and although much can be learned about the behavioural or pathological condition of interest, construct validity is not necessary for an effective animal model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>What do DOI-elicited HTRs model?</head><p><s>The DOI-elicited HTR has been considered as an animal model of a variety of behavioral and psychiatric conditions including hallucinogenesis, schizophrenia, obsessive-compulsive disorders, Tourette's syndrome, and more generally as a model of 5-HT 2 function/activity.</s><s>Although the DOI-elicited HTR has some validity as a model for each of these conditions, it is likely most suitable as a model of 5-HT 2 receptor activity, as described below.</s></p><p><s>Hallucinogenesis-Many hallucinogenic 5-HT 2 receptor agonists produce the HTR in rodents, and early animal studies of hallucinogens suggested that this response may be a model of hallucinating. <ref type="bibr" target="#b42">[43]</ref></s><s>The consistently reproduced observations that 5-HT 2 receptor antagonists, such as those that block the hallucinogenic effects of classical hallucinogens, such as psilocybin, <ref type="bibr" target="#b168">[169]</ref> completely block the hallucinogen-induced HTR bolster support for the HTR as a model of hallucinating, and for 5-HT 2 receptor activation as the underlying mediator of hallucinogenesis.</s><s>Moreover, nonhallucinogenic compounds with 5-HT 2A agonist activity, for example, lisuride, fail to produce the HTR. <ref type="bibr">[94]</ref></s><s>The HTR model itself (excluding the DOI-elicited HTR model), however, falls short of directly modeling hallucinations in humans, because a much larger list of compounds, including but not limited to the serotonin precursor, 5-HTP, the 5-HT releasing agent, fenfluramine, and the cannabinoid receptor antagonist, SR141716A, that are known to lack hallucinogenic activity in man, nevertheless produce the HTR in rodents. <ref type="bibr" target="#b42">[43,</ref><ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b146">147,</ref><ref type="bibr" target="#b236">237]</ref></s><s>Also, compounds, including DMT, that are hallucinogenic in man do not reliably produce the HTR. <ref type="bibr" target="#b45">[46]</ref></s><s>However, the HTR is a good model of 5-HT 2 receptor activation in the rodent, as to our knowledge 5-HT 2 receptor antagonists have blocked the HTR induced by every compound tested, and all compounds of which we are aware that have been shown consistently to be potent b and selective agonists for 5-HT 2A, 2B , and 2C receptors induce the HTR.</s><s>Nevertheless, the DOIelicited HTR itself may still be useful as a tool to investigate (as best as the rodent brain will permit) neural mechanisms that may produce or underlie hallucinogenic effects caused by psychedelic drugs.</s></p><p><s>For reasons similar to the HTR model, the rodent drug-discrimination model also fails to model hallucinogenesis.</s><s>For example, both LSD and DOM stimuli generalize with the nonb notably DMT has relatively poor affinity for 5-HT 2A receptors, [40] yet we could not find in the literature DMT's affinity for 5-HT 2C receptors.</s></p><p><s>hallucinogenic compounds, fenfluramine and lisuride, <ref type="bibr" target="#b237">[238,</ref><ref type="bibr" target="#b238">239]</ref> and much of the stimulus effect of lisuride is likely mediated by 5-HT 2A receptor activation. <ref type="bibr" target="#b238">[239]</ref></s><s>In other words, 5-HT 2A receptor activation in the rodent by lisuride and LSD may produce similar cognitive effects in rodents, i.e. rodents may not always be able to distinguish hallucinogenic (LSD) from non-hallucinogenic (lisuride).</s><s>Moreover, there is some evidence that activity at 5-HT 1A receptors can modulate the discriminative stimulus effects of hallucinogens (e.g.</s><s>5-HT 1A agonists produce partial substitution and enhance, while antagonists can partially block the effects of LSD), <ref type="bibr" target="#b239">[240,</ref><ref type="bibr" target="#b240">241]</ref> yet results from a plethora of studies suggest 5-HT 1A receptor activation does not cause hallucinogenic effects in humans. <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b91">92]</ref></s><s>Indeed, antagonism of 5-HT 1A receptors by pindolol potentiates the psychological responses to DMT in humans. <ref type="bibr" target="#b241">[242]</ref></s><s>Again a disclaimer arises, as pindolol may have weak partial agonist activity at 5-HT 1A receptors in vivo.</s><s>In conclusion, subjective (i.e.</s><s>drug discrimination) as well as observable (i.e.</s><s>HTR) behavioural effects observed in rodents after administration of hallucinogens are better conceived as pharmacological outcomes, and not models of hallucinating.</s></p><p><s>Schizophrenia-Shortly after the discovery of psychedelic hallucinogens, similarities between the subjective effects of these compounds and the perceptual effects associated with schizophrenia and related psychosis-related disorders were noted. <ref type="bibr" target="#b242">[243,</ref><ref type="bibr" target="#b243">244]</ref></s><s>Early reports suggested that administration of hallucinogenic drugs to animals could function as a model of schizophrenia. <ref type="bibr" target="#b244">[245]</ref></s><s>It may be that drug-elicited head-twitches are a simple model of the 'positive symptoms' (in particular, hallucinations) associated with schizophrenia rather than a model of the entire syndrome of schizophrenia.</s><s>This would be a classic example of an animal model that initially is proposed as a model of the entire syndrome of interest, which is later tapered down to potentially being a model of an endophenotype of a particular syndrome. <ref type="bibr" target="#b245">[246]</ref></s><s>rrent conceptions of the pathophysiology of schizophrenia have been derived largely from pharmacological studies and can be summarized as follows.</s><s>Dopamine agonists such as amphetamine, 5-HT 2A receptor agonists that are psychedelics (e.g.</s><s>LSD), and glutamate NMDA receptor antagonists including PCP, MK-801, and ketamine can all produce psychosis-like behavioural and subjective effects in humans.</s><s>Conversely, dopamine D 2 antagonists, 5-HT 2A receptor antagonists, and glutamate mGluR 2/3 receptor agonists are to some extent effective antipsychotic medications.</s></p><p><s>Data obtained using DOI-elicited HTRs and pharmacological challenges are generally consistent with this notion.</s><s>In particular, much data suggests that glutamate NMDA receptor antagonists exacerbate the HTR, mGluR 2/3 receptor agonists and antagonists attenuate and enhance the HTR respectively, 5-HT 2A antagonists block the HTR, and dopamine D 2 receptor and D 1 receptor antagonists block the HTR.</s><s>Post-mortem study of brains from schizophrenic patients, <ref type="bibr" target="#b136">[137,</ref><ref type="bibr" target="#b246">247]</ref> and PET studies of untreated, first-episode psychotic patients demonstrated altered levels of 5-HT 2A receptors which appear to corroborate these findings.</s></p><p><s>Of particular interest regarding the use of this model as a model of schizophrenia is that essentially every effective antipsychotic medication used in humans is effective in attenuating the HTR elicited by DOI administration.</s><s>That is, there seem to be relatively few 'false negatives' -drugs that are useful as antipsychotic medications that fail to block the HTR.</s><s>While this is an interesting set of findings, one issue that has recently become apparent is that blockade of the DOI-elicited HTR in mice does not necessarily translate to antipsychotic activity in humans.</s><s>This is most clearly demonstrated by clinical studies examining the highly selective 5-HT 2A receptor antagonist M100907, which has extraordinary potency at blocking the DOI-elicited HTR.</s><s>Although originally developed as a novel antipsychotic, <ref type="bibr" target="#b247">[248]</ref> M100907 c apparently failed in clinical trials for the treatment of schizophrenia. <ref type="bibr" target="#b248">[249]</ref></s><s>Although we believe that positive results in DOI-elicited HTR behavioural procedures may be indicative of antipsychotic activity, these results highlight the fact that findings obtained from one animal model are not enough to draw strong conclusions about pharmacotherapeutic implications.</s><s>Rather, convergent evidence from the use of many animal models is required.</s><s>So although M100907 was not effective in human trials, the fact that it may show up as a 'false positive' in DOI-elicited HTR studies does not necessarily indicate the model is useless.</s><s>Rather, this animal model represents one tool at researchers' disposal that may help to identify a desired preclinical profile indicative of antipsychotic activity in humans.</s></p><p><s>One particularly interesting study exploring the relationship between DOI-elicited HTR and schizophrenia was one in which the effects of various other symptoms commonly associated with the disorder, i.e. poorly-structured sleep and suppressed endogenous opioid function, were assessed in combination with DOI-elicited HTRs. <ref type="bibr" target="#b249">[250]</ref></s><s>In this study, the effects of sleep disturbances were modelled by a period of sleep deprivation and suppressed opioid function was induced by administration of the opioid antagonist naloxone.</s><s>Neither treatment alone had effects on the sensitivity of HTRs to DOI.</s><s>The combination, however, of sleep deprivation and naloxone treatment significantly enhanced sensitivity to DOI.</s></p><p><s>Epidemiologically, gestational exposure to infection is associated with high risk of developing schizophrenia in adult offspring. <ref type="bibr" target="#b250">[251]</ref></s><s>Another recent and interesting paper using mice demonstrated that maternal influenza viral infection increased sensitivity to DOI (approximately twice as many HTRs) in the adult (but not prepubertal) offspring. <ref type="bibr" target="#b135">[136]</ref></s><s>ontinued exploration of the model in this matter may provide substantial etiological validity that could contribute to the development of novel treatments for schizophrenia.</s></p><p><s>Obsessive-compulsive disorder (OCD) and Tourette's syndrome-OCD incorporates a variety of related behavioural pathologies, and Tourette's syndrome is typically considered as part of the OCD spectrum.</s><s>One symptom associated with these disorders is the presence of a tic, and the DOI-elicited HTR has been described as an analogous behavioural outcome.</s><s>As an animal model of tic disorders, the DOI-elicited HTR seems to have some face validity (i.e. the HTR may look like a tic).</s><s>It is possible, although unknown at this point in time, that there is some etiological validity if tics are indeed produced by an over-stimulation of 5-HT 2A receptors.</s><s>Importantly, the model appears to have some predictive validity in one direction: the only medications that appear to be useful in treating tics, such as haloperidol (primarily a dopamine D 2 antagonist), atypical opioids (levorphanol, tramadol), nicotine (acetylcholine agonist), and donepezil (acetylcholine esterase inhibitor; indirect acetylcholine agonist), are effective in suppressing DOI-elicited head-twitches. <ref type="bibr" target="#b62">[63,</ref><ref type="bibr" target="#b139">140,</ref><ref type="bibr" target="#b152">153,</ref><ref type="bibr" target="#b153">154,</ref><ref type="bibr" target="#b251">252]</ref></s><s>Unfortunately the preclinical literature and clinical outcome research exploring the potential relationship between DOI-elicited HTR and OCD/Tourette's syndrome is relatively limited, so firm conclusions cannot be made at this time.</s></p><p><s>Involvement of 5-HT 2A receptor activity and status of the 5-HT 2A system-It may be relatively safer to suggest that the HTR elicited by DOI and related compounds can be effectively used as in vivo behavioural models to study 5-HT 2A receptor pharmacology, however as noted above, drugs from many pharmacological classes can alter DOI-elicited HTRs.</s><s>Thus, if a novel drug attenuates or enhances the DOI-elicited HTR, one cannot with certainty conclude anything about the pharmacological mechanism of action.</s></p><p><s>c This compound is currently being evaluated for the treatment of insomnia and treatment resistant depression: www.clinicaltrials.gov.</s></p><p><s>A number of investigators have used sensitivity to DOI (measuring the HTR) as a measure of the functional status of an animal's 5-HT 2A receptor system.</s><s>That is, the animal is exposed to some environmental, pharmacological, or genetic manipulation, and the state of the 5-HT 2A system is inferred from the number of HTRs elicited by DOI administration.</s><s>In many instances, sensitivity to DOI is highly correlated with the number and/or function of 5-HT 2A receptors; for example, Rinaldi-Carmona et al. <ref type="bibr" target="#b252">[253]</ref> demonstrated that chronic administration of a novel 5-HT 2A antagonist upregulated 5-HT 2A receptor density and increased sensitivity to DOI (see Dougherty and Aloyo <ref type="bibr" target="#b73">[74]</ref> for a more comprehensive discussion of repeated drug administration, changes in receptor density, and sensitivity to DOI).</s><s>It should be noted, however, that there are situations (e.g.</s><s>across mouse strains) where sensitivity to DOI does not correlate with 5-HT 2A density. <ref type="bibr" target="#b64">[65]</ref></s><s>Thus, interpretations about the 5-HT 2A receptor system following a single experiment with DOI should be corroborated using additional models to provide convergent evidence regarding a particular scientific question.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p><s>The DOI-elicited HTR has been used as an animal model of a variety of behavioural and psychiatric conditions.</s><s>As described above, there is reasonable evidence that these models may have some predictive validity, especially regarding pharmacological interventions in each case.</s><s>However, simply because a model has some form of validity, one should not infer that the model incorporates all aspects of the behaviour or condition under investigation.</s><s>That is, DOI-elicited HTRs should not be considered hallucinogenic episodes, or a way to examine the entire syndromes called schizophrenia, Tourette's syndrome, or obsessivecompulsive disorder.</s><s>Similarly, the neuropharmacology of DOI, along with the pharmacology of essentially every other psycho-active drug ever examined is relatively complex.</s><s>Furthermore, activity in the head-twitch model itself is not de facto proof of action at the 5-HT 2A receptor as described above.</s><s>Rather these procedures can be useful as one of many tools for examining a particular aspect of these disorders, and that progress will only be made when there is convergent evidence using a number of models.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>The DOI-induced HTR is a relatively straightforward behavioural and pharmacological procedure to set up and quantify, and can be used to ask interesting questions about neuropharmacological mechanisms and complex behavioural and psychiatric conditions.</s><s>Various unresolved issues remain regarding behavioural neuropharmacological effects of DOI; therefore, there is much reason to continue using this procedure.</s><s>There is increasing interest in the therapeutic potential of both 5-HT 2A , as well as 5-HT 2C , receptor agonists and antagonists for a variety of conditions.</s><s>In addition to various psychiatric disorders mentioned above (e.g.</s><s>psychosis-related disorders and OCD), the 5-HT 2 receptor system has been identified as a desirable drug target for the treatment of depression, anxiety, posttraumatic stress disorder, obesity, numerous pain conditions (inflammation, neuropathic pain, cluster headaches), cardiovascular disease, and various sleep disorders (recent reviews <ref type="bibr" target="#b253">[254,</ref><ref type="bibr" target="#b258">259]</ref> ).</s><s>Hallucinogenic 5-HT 2 receptor agonists, in addition, are receiving renewed attention as potential psychotherapeutic agents. <ref type="bibr" target="#b259">[260,</ref><ref type="bibr" target="#b260">261]</ref></s><s>Others have noted, however, that 5-HT 2A receptor activation may potentially limit the therapeutic properties of other neuropsychiatric medications (e.g.</s><s>SSRIs), suggesting combination therapies that include 5-HT 2A antagonists. <ref type="bibr" target="#b261">[262]</ref></s><s>Notably, there is not a lot of support to develop selective 5-HT 2B agonists, as activation of 5-HT 2B receptors in heart tissue is associated with valvular heart disease. <ref type="bibr" target="#b262">[263,</ref><ref type="bibr" target="#b263">264]</ref></s><s>Given the great potential for therapeutic agents targeting 5-HT 2 systems, relevant animal models need to be used and improved, in order to advance drug discovery programs.</s><s>The DOI-induced HTR is one model that can help contribute to this effort.</s></p><p><s>In conclusion, DOI's hallucinogenic effects may be likened to a symphony orchestra conducted in the brain, with the receptors it activates, the sections or instruments.</s><s>With this analogy, DOI-induced activation of 5-HT 2A receptors sets the melody of the experience, and the other instruments, such as 5-HT 2B , 5-HT 2C , and potentially adrenergic receptors, play accompanying roles.</s><s>With each receptor an instrument, DOI has a number of them to play.</s></p><p><s>To argue that performance of only one instrument, i.e. the 5-HT 2A receptor, produces the total psychedelic experience while the other instruments are plugged in and turned on but not played, seems indefensible.</s><s>In other words, as pointed out by other researchers, <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b92">93,</ref><ref type="bibr" target="#b237">238]</ref> activation of 5-HT 2A receptors, may be necessary, but not sufficient to produce the full range of effects of DOI.</s><s>Cumulative number of head-twitch responses (HTRs) following administration of various doses of (-)-DOI (mg/kg; IP) to male, C57Bl/6J mice.</s><s>Each mouse (n = 4) was tested with all four doses (in random order) at approximately 1-week intervals.</s><s>HTRs were counted in 2-min periods, every 10 min, beginning immediately following administration of drug.</s><s>Note that (-)-DOI elicited HTRs began within the first 2-min period (Time 0), the frequency of HTRs were dose-dependent, and HTRs continued throughout the 2-h testing period.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Commercial (a) and IUPAC (b) nomenclature for DOI.</s></p></div></figDesc><graphic coords="39,151.38,61.00,369.24,183.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2.</s></p></div></figDesc><graphic coords="40,198.14,61.00,275.71,288.72" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p><s>Drug Test Anal.</s><s>Author manuscript; available in PMC 2013 July 25.</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>The authors thank <rs type="person">Krishnakanth Kondabolu</rs> for assistance in collecting the data presented in Figure 2. The authors were partially supported by a grant from the <rs type="funder">National Institutes of Health</rs> (<rs type="grantNumber">R01 DA030989</rs>) awarded to <rs type="person">Raymond G. Booth</rs>.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_Z4jpHxP">
					<idno type="grant-number">R01 DA030989</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Head-twitch response (HTR) induced by DOI (mg/kg, i.p. or s.c.) across rodent species and strains.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Species and strains Dose, enantiomer HTRs</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Titeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page">23</biblScope>
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note>PubMed: 6479216</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Differentiation of 5-hydroxytrypta-mine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo phenylisopropylamine and 3H-ketanserin</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Peroutka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">3482</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2795135</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Pharmacological characterisation of the agonist radio-ligand binding site of 5-HT(2A)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Misra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Quirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Benwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Revell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bickerdike</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N-S. Arch. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">114</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>B) and 5-HT(2C) receptors</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B-and 5-HT2-receptor interactions</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">95</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Behavioral and serotonin receptor properties of 4substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Benington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1163</biblScope>
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note>PubMed: 7143352</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Pihkal: A Chemical Love Story</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shulgin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shulgin</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1990">1990</date>
			<publisher>Transform Press</publisher>
			<pubPlace>Berkeley, CA, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Stereospecific requirements for hallucinogenesis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shulgin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharm. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">271</biblScope>
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
	<note>PubMed: 4146335</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Structure-activity relationships in psychotomimetic phenylalkylamines</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Aldous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Barrass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brewster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Buxton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Pinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Skeels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Tutt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">1100</biblScope>
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
	<note>PubMed: 4418757</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Comparative effects of stereoisomers of hallucinogenic amphetamines</title>
		<author>
			<persName><forename type="first">F</forename><surname>Benington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Smythies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bradley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. New Biol</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="page">185</biblScope>
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
	<note>PubMed: 4512757</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Choroid plexus epithelial cells in primary culture: A model of 5HT1C receptor activation by hallucinogenic drugs</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Breeding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page">340</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>PubMed: 1665919</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<title level="m">Mechanism of tolerance development to 2,5-dimethoxy-4iodoamphetamine in rats: Down-regulation of the 5-HT2A, but not 5-HT2C, receptor. Psychopharmacology (Berl)</title>
		<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page">248</biblScope>
		</imprint>
	</monogr>
	<note>PubMed: 10435391</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">AT. 4-aklyl-dialkoxy-alpha-methyl-phenethylamines and their pharmacologicallyacceptable salts</title>
		<author>
			<persName><surname>Shulgin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">U.S. Patent</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">999</biblScope>
			<date type="published" when="1970-12">1970. Dec. 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shulgin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Naranjo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacology</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">103</biblScope>
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
	<note>PubMed: 5570923</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4methylphenyl)-2-aminopropane (DOM)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Coutts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Malicky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can. J. Chem</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page">1402</biblScope>
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">The Shulgin Index: Volume One</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shulgin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Manning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Daley</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>Transform Press</publisher>
			<pubPlace>Berkeley, CA, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mathis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Shulgin</surname></persName>
		</author>
		<author>
			<persName><surname>Sargent T 3rd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Saavedra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page">289</biblScope>
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note>PubMed: 3609149</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT (2A) and 5f-HT(2C) receptors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Egan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Grinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dupre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Teitler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Herrick-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synapse</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page">144</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10611640</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Nichols</forename><forename type="middle">De</forename><surname>Hallucinogens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Therapeut</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page">131</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Benwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lamb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Malcolm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Revell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sheardown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">13</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10498829</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Lucaites</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Wainscott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N-S. Arch. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: Evidence for species differences</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Wainscott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Lucaites</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kursar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="issue">720</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8632342</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrasment of riches?</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Kroeze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lopez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Neuroscientist</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">252</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Psychedelics and the human receptorome</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Ray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20126400</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Regulation of serotonin-2C receptor G-protein coupling by RNA editing</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rueter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Canton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Emeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page">303</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9153397</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Serotonin 5-ht2 receptors: Molecular and genomic diversity</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fentress</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hazelwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Interv</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">319</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14993464</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Niswender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Herrick-Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Emeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">274</biblScope>
			<biblScope unit="page">9472</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10092629</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Messenger RNA editing of the human serotonin 5-HT2C receptor</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Iyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Conklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Jonak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hartig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">82</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10432493</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms</title>
		<author>
			<persName><forename type="first">S</forename><surname>Marion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Caron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page">2945</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14602721</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Impact of RNA editing on functions of the serotonin 2 C receptor in vivo</title>
		<author>
			<persName><forename type="first">Olaghere</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">B</forename><surname>Morabito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Canal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Airey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Emeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Neurosci</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20582266</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Lopez-Gimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Villazon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Loza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Palacios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mengod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Vilaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">690</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11562430</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maayani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Goldfarb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Scaramellini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page">94</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9658194</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Moya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gutierrez-Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saez-Briones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reyes-Parada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Cassels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="page">17337633</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Cropper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Niswender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Emeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page">386</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11564657</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cussac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Newman-Tancredi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Quentric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carpentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Poissonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Parmentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N-S. Arch. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page">242</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page">1373</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8819525</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Duxon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Flanigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Reavley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Blackburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page">323</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9015317</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Serotonin-facilitated dopamine release in vivo: pharmacological characterization</title>
		<author>
			<persName><forename type="first">S</forename><surname>Benloucif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Keegan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Galloway</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">265</biblScope>
			<biblScope unit="page">373</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8474019</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: Effect of antipsychotic drugs</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bortolozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Amargos-Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Adell</forename><forename type="middle">A</forename><surname>Diaz-Mataix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Serrats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Artigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">1235</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12956722</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Molecular biology of 5-HT receptors</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Boess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">275</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7984267</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Hallucinogenic drug interactions at human brain 5-HT2 receptors: Implications for treating LSD-induced hallucino-genesis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sadzot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Baraban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Lyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leonhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Titeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page">495</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2505289</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Permanent alteration of behavior in mice by chemical and psychological means</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Umbreit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page">723</biblScope>
			<date type="published" when="1956">1956</date>
		</imprint>
	</monogr>
	<note>PubMed: 13371313</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Corne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Pickering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Warner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol. Chemother</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">106</biblScope>
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
	<note>PubMed: 14023050</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">A possible correlation between drug-induced hallucinations in man and a behavioural response in mice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Corne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Pickering</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacologia</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">65</biblScope>
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
	<note>PubMed: 5302272</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fantegrossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Reissig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Yarosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page">358</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fantegrossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Kiessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eckler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Woods</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page">122</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fantegrossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eckler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arshad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Woods</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page">496</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15983786</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Koedood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1548</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 21148021</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The serotonin 5-HT2A receptor agonist TCB-2: A behavioral and neurophysiological analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laporte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blackler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="issue">13</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19823806</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Central serotonin-like activity of 6-chloro-2-[1piperazinyl]-pyrazine (CPP; MK-212)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Clineschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mcguffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Pflueger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page">65</biblScope>
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note>PubMed: 885160</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Head-twitch response induced by ergometrine in mice: Behavioural evidence for direct stimulation of central 5-hydroxytrypta-mine receptors by ergometrine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Balsara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Bapat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Nandal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Gada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Chandorkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page">275</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 2938207</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenflura-mine-induced head-twitch response in mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">83</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Titeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Mckenney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page">2505</biblScope>
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note>PubMed: 6513725</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">A proposed new nomenclature for 5-HT receptors</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Humphrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hartig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hoyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Pharmacol. Sci</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">233</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8372403</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Fozard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hartig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Mylecharane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Saxena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Humphrey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Rev</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page">157</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7938165</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI</title>
		<author>
			<persName><forename type="first">J</forename><surname>Arnt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hyttel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2524390</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Do functional relationships exist between 5-HT1A and 5-HT2 receptors?</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">901</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Scarlota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Aloyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="issue">393</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 20652541</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Dave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Aloyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">371</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2-and not a 5-HT1C-mediated phenomenon</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">B</forename><surname>Mock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Towns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Gerdes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">383</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The involvement of sub-types of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Tricklebank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Forler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Fozard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page">271</biblScope>
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note>PubMed: 6241568</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Temporal differential adaptation of head-twitch and ear-scratch responses following administration of challenge doses of DOI</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Gerdes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">545</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/-)-1-(2,5-dimethoxy-4iodophenyl)-2-aminopropane (DOI) or ketanserin</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">262</biblScope>
			<biblScope unit="page">692</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1501117</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior</title>
		<author>
			<persName><surname>Rojas-Corrales</surname></persName>
		</author>
		<author>
			<persName><surname>Mo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gibert-Rahola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mico</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page">17102981</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists</title>
		<author>
			<persName><forename type="first">R</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brocco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Audinot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gobert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Veiga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page">101</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7714755</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">The serotonin 2 C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Canal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Olaghere</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">B</forename><surname>Gresch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Watt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Airey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="page">163</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20165943</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Repeated adolescent MDMA (&quot;Ecstasy&quot;) exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Biezonski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Courtemanche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Piper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">1252</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19059385</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Diabetes inhibits the DOI-induced head-twitch response in mice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Miyata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hirano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kamei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page">15290007</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine-and haloperidol-induced hypothermia in mice</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sugimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Horisaka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol. Pharm. Bull</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">1580</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8593484</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kleven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Assie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Koek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page">747</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9262338</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Withdrawal from chronic treatment with (+/-)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page">115</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2282932</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Inhibition of 5-HT2 receptor-mediated headtwitch response by cocaine via indirect stimulation of adrenergic alpha 2 and serotonergic 5-HT1A receptors</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">353</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Pranzatelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci. Lett</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page">74</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2216059</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fantegrossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simoneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Zimmerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Henson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Woods</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="page">728</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Dougherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Aloyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">215</biblScope>
			<biblScope unit="page">581</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21340474</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Gewirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">569</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11027922</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">A genetic screen for mouse mutations with defects in serotonin responsiveness</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Pawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Cordes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res. Mol. Brain Res</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page">162</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12877987</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Differential ontogenesis of three DOI-induced behaviors in mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shaddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Gerdes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol. Behav</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">1495</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8946497</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Hallucinogenic 5-hydroxytrypta-mine 2A receptor agonist effects in senescence-accelerated mice</title>
		<author>
			<persName><forename type="first">K</forename><surname>Niimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Itakura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp. Anim</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page">441</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20660990</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Age-associated changes in the serotonergic system in rat superior colliculus and pretectum</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Parsons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Benca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brownfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res. Bull</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page">435</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11489352</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">5-HT 1A and 2A receptor positive cells in the cerebella of mice and human and their decline during aging</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Yew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Yeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Mak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Microsc. Res. Tech</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">684</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19353636</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume corrections</title>
		<author>
			<persName><forename type="first">H</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Mamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kapur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Mulsant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Houle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Pollock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Graff-Guerrero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Geriatr. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<date type="published" when="1300">2011. 1300</date>
		</imprint>
	</monogr>
	<note>PubMed: 21351153</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population</title>
		<author>
			<persName><forename type="first">Moses-Kolko</forename><surname>El</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Berga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sereika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Mason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Loucks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Meltzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<date type="published" when="2011">2011. 2729</date>
		</imprint>
	</monogr>
	<note>PubMed: 21849982</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Factors modifying the head-twitch response to 5-hydroxytryptophan</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Boulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacologia</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">205</biblScope>
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
	<note>PubMed: 4542469</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Modulation by 5-HT2A receptors of aggressive behavior in isolated mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sakaue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sowa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sakamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nishihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Koyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Matsuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page">89</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Region specific changes in forebrain 5-hydroxytryptamine1A and 5-hydroxytryptamine2A receptors in isolation-reared rats: an in vitro autoradiography study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Preece</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Dalley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Theobald</forename><forename type="middle">De</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page">725</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14706784</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Acute immobilization stress reduces (+/-)DOIinduced 5-HT2A receptor-mediated head shakes in rats</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nankai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toru</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">7675955</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Swim stress inhibits 5-HT2A receptor-mediated head twitch behaviour in mice</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pericic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page">373</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12695874</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Effects of chlorisondamine and restraint on cortical [3H]ketanserin binding, 5-HT2A receptor-mediated head shakes, and behaviours in models of anxiety</title>
		<author>
			<persName><forename type="first">F</forename><surname>Chaouloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baudrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Coupry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page">449</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7984283</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Cortical [3H]ketanserin binding and 5-HT2A receptor-mediated behavioral responses in obese Zucker rats</title>
		<author>
			<persName><forename type="first">F</forename><surname>Chaouloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Coupry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baudrie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">309</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Effects of cold stress on some 5-HT1A, 5-HT1C and 5-HT2 receptor-mediated responses</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zamfir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Broqua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baudrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chaouloff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">219</biblScope>
			<biblScope unit="page">261</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1385172</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">The behavioral pharmacology of hallucinogens</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Fantegrossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Murnane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Reissig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page">17</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 17977517</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">364</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21256140</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Animal Models for Assessing Classical Hallucinogens</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Animal Models of Drug Addiction</title>
		<editor>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Boulton</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Baker</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</editor>
		<meeting><address><addrLine>Clifton, NJ, USA</addrLine></address></meeting>
		<imprint>
			<publisher>Humana Press</publisher>
			<date type="published" when="1992">1992</date>
			<biblScope unit="page" from="345" to="381" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Weisstaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page">17270739</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kehne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Carr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page">968</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8627580</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Sharif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>France</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page">307</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>]indazol-1-yl)-1methylethylamine]</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kursar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Wainscott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page">227</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 8078486</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Bonhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Desouza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Matsuoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zuppan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Eglen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page">622</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7582481</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: Absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Penner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dorow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Pertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jahnichen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Horowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Latte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Palla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schurad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Neuropharmacol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">80</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16614540</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Deconstructing antiobesity compound action: Requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Banas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Doly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boutourlinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Belmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Callebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Collet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-M</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maroteaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">423</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 20927048</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro</title>
		<author>
			<persName><forename type="first">S</forename><surname>Doly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Valjent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Setola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Callebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Herve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Launay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maroteaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">2933</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18337424</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page">251</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 18979087</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Serotonergic receptor subtypes and hallucinogen-induced stimulus control</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Fiorella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Timineri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Filipink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Helsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page">283</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">6-Chloro-5-methyl-1-[[2-[(2-methyl-3pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): The first selective and brain penetrant 5-HT2C receptor antagonist</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Bromidge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Duckworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Forbes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">3494</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9357513</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">609</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9225286</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">A 5-HT(2C) receptor-mediated interaction between 2,5-dimethoxy-4-methylampheta-mine and citalopram in the rat</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eckler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Reissig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page">25</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Willins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page">699</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9262333</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Simansky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Schechter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">247</biblScope>
			<biblScope unit="page">1073</biblScope>
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>PubMed: 3144595</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Behavioural evidence for functional interactions between 5-HTreceptor subtypes in rats and mice</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Berendsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Broekkamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">667</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2150180</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Booth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Blackburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Glen</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">2524</biblScope>
			<date type="published" when="1995">5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,. 1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7629791</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Discriminative stimulus properties of 1</title>
		<editor>
			<persName><surname>C57bl/6j Mice</surname></persName>
		</editor>
		<imprint>
			<date type="published" when="2003">2,5-dimethoxy-4iodophenyl)-2-aminopropane. 2003</date>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page">61</biblScope>
		</imprint>
	</monogr>
	<note>PubMed: 12474110</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Van Der Heijden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ruderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">B</forename><surname>Risbrough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Powell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="1958">2009. 1958</date>
		</imprint>
	</monogr>
	<note>PubMed: 19322172</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Malcolm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bickerdike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page">643</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Glen</forename><forename type="middle">A</forename><surname>Grewal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gadre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blackburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page">797</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7912626</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Gresch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page">662</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17077317</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jenck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Moreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Sleight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Widmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">2762</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9276022</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">CP-809,101, a selective 5-HT2C agonist shows activity in animal models of antipsychotic activity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Siuciak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Chapin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Guanowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Swick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Iredale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">279</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 16949622</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kumaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Morency</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Toth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shuster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem. Lett</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">4555</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 16061378</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Functional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page">879</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20128812</note>
</biblStruct>

<biblStruct xml:id="b119">
	<monogr>
		<title level="m" type="main">Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2aminopropane (DOI)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Wettstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Host</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hitchcock</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
			<publisher>Prog. Neuro-Psychoph</publisher>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">533</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">5-HT2A/2 C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villacreses</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Rapoport</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page">12</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15834538</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems</title>
		<author>
			<persName><forename type="first">J</forename><surname>Maj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rogoz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural Transm</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page">197</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10226939</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems</title>
		<author>
			<persName><forename type="first">J</forename><surname>Maj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rogoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dlaboga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dziedzicka-Wasylewska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural Transm</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page">1345</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11145008</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">The effect of the repeated administration of the compound 3,4methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C receptor agonist (+/ -)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Granoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Ashby</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychobiology</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">36</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9438270</note>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Head twitches induced by LSD and quipazine: similarities and differences</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vetulani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bednarczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Reichenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rokosz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">155</biblScope>
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
	<note>PubMed: 6244515</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Involvement of the locus coeruleus in the potentiation of the quipazineinduced head-twitch response by diazepam and beta-adrenoceptor agonists</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1315</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 2882436</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Behavioral effects of quipazine in the cat</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Trulson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Brandstetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Crisp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Jacobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page">295</biblScope>
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note>PubMed: 6461558</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">The 5-HT7 receptor and disorders of the nervous system: an overview</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Hedlund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="page">345</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19649616</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ishibashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Horisawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tokuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="page">171</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20404009</note>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Patil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Martenyi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">17767166</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<monogr>
		<title level="m" type="main">AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>Prog. Neuro-Psychoph</publisher>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page">62</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page">2305</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9877220</note>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dall'olio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gaggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bonfante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Gandolfi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">63</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice</title>
		<author>
			<persName><forename type="first">A</forename><surname>Klodzinska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bijak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tokarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pilc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">327</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Role of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice</title>
		<author>
			<persName><forename type="first">N</forename><surname>Egashira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shirakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Okuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mishima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iwasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Oishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujiwara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Holloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Albizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Sealfon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci. Lett</title>
		<imprint>
			<biblScope unit="volume">493</biblScope>
			<biblScope unit="issue">76</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21276828</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Identification of a serotonin/glutamate receptor complex implicated in psychosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yuen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">452</biblScope>
			<biblScope unit="page">93</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18297054</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Involvement of diazepam-insensitive benzodiazepine receptors in the suppression of DOI-induced head-twitch responses in diabetic mice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Miyata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hirano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kamei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16555059</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wieronska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kusek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tokarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wabno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Froestl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pilc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<date type="published" when="1034">2011. 1034</date>
		</imprint>
	</monogr>
	<note>PubMed: 21371011</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: Implications for Tourette&apos;s syndrome</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Hayslett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tizabi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page">879</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Dursun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<date type="published" when="0198">1996. 198</date>
		</imprint>
	</monogr>
	<note>PubMed: 8956381</note>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Horiguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Massey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="page">289</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21212939</note>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscientist</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">452</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 16151046</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine&apos;s actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page">269</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">The effects of acute cocaine administration on the DOI-induced head-twitch response in reserpinized mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page">229</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptormediated behaviors in mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page">311</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Pandya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural Transm</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page">931</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11041273</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Janoyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Crim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page">155</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rinaldi-Carmona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Barth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heaulme</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page">240</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 8070571</note>
</biblStruct>

<biblStruct xml:id="b149">
	<monogr>
		<title level="m" type="main">Anandamide inhibits the DOI-induced head-twitch response in mice</title>
		<author>
			<persName><forename type="first">N</forename><surname>Egashira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mishima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hasebe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mizuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iwasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ishii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujiwara</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2004">2004</date>
			<publisher>Psycho-pharmacology (Berl)</publisher>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page">382</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Regehr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">6508</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18562622</note>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Tzavara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Bymaster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Witkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Nomikos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page">544</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12598408</note>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Effects of nicotine on head-shakes and tryptophan metabolites</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gaynor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page">327</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11271405</note>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Nicotine attenuates DOI-induced head-twitch response in mice: Implications for Tourette syndrome</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Tizabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Darmani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog. Neuro-Psychoph</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1445</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">The modulation of head-twitch behaviour by drugs acting on betaadrenoceptors: evidence for the involvement of both beta 1-and beta 2-adrenoceptors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page">320</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 2870532</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Involvement of noradrenaline in potentiation of the head-twitch response by GABA-related drugs</title>
		<author>
			<persName><forename type="first">L</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Heaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page">315</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 2870531</note>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">The influence of central noradrenergic function on 5-HT2-mediated head-twitch responses in mice: Possible implications for the actions of antidepressant drugs</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Heal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Philpot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page">414</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>PubMed: 3018823</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Effects on the 5-hydroxytryptamine-induced head-twitch of drugs with selective actions on alpha1 and alpha2-adrenoceptors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Handley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">507</biblScope>
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note>PubMed: 6125909</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page">1082</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19324062</note>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Adenosine A(1) and A (3) receptors mediate inhibition of synaptic transmission in rat cortical neurons</title>
		<author>
			<persName><forename type="first">A</forename><surname>Brand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Vissiennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nieber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">85</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11077074</note>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Behavioral evidence for mu-opioid and 5-HT2A receptor interactions</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">474</biblScope>
			<biblScope unit="page">77</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12909198</note>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Intraventricular injections of galanin counteract development of head twitches induced by the 5-HT-2 agonist 1-(2,5-dimethoxyphenyl-4-bromo)-2-aminopropane</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Ogren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fuxe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Physiol. Scand</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page">297</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note>PubMed: 2476910</note>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Effects of galanin on 8-OH-DPAT induced decrease in body temperature and brain 5-hydroxytryptamine metabolism in the mouse</title>
		<author>
			<persName><forename type="first">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Hutson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page">197</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8997601</note>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse-2. Caesium</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grahame-</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">421</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse-3. Quinine</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grahame-</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">425</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1388254</note>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse-1</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grahame-</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rubidium. Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">413</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1382243</note>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">The neurobiology of psychedelic drugs: implications for the treatment of mood disorders</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kometer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Neurosci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">642</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20717121</note>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">Brain mechanisms of hallucinogens and entactogens</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dialogues Clin. Neurosci</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">265</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 22033605</note>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Vollenweider-Scherpenhuyzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Babler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">3897</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9875725</note>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">The integration of negative affect, pain and cognitive control in the cingulate cortex</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Shackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Salomons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Slagter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Davidson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Neurosci</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">154</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21331082</note>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Andrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Neurosci</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">36</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20802802</note>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Jakab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">735</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>PubMed: 9435262</note>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: Normative data and relationship to physiological and demographic variables</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Pinborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Svarer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Hasselbalch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Holm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haugbol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Madsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Frokjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Martiny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">B</forename><surname>Paulson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Knudsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroimage</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">1105</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15006678</note>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Miner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Backstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Sesack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page">107</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12535944</note>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Seroogy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lundgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jennes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Comp. Neurol</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page">357</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7706547</note>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Willins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Deutch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synapse</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">79</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9268067</note>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Mengod Mapping of G. 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Lopez-Gimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Vilaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Palacios</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Comp. Neurol</title>
		<imprint>
			<biblScope unit="volume">429</biblScope>
			<biblScope unit="page">571</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11135236</note>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex</title>
		<author>
			<persName><forename type="first">N</forename><surname>Santana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bortolozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Serrats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mengod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Artigas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cereb. Cortex</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1100</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs</title>
		<author>
			<persName><forename type="first">P</forename><surname>Celada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diaz-Mataix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Artigas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol. Psychiat</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page">392</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18436196</note>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">Mechanism of the 5hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Beique</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Imad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mladenovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Andrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page">9870</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17535909</note>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">589</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9225284</note>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">825</biblScope>
			<biblScope unit="page">161</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10216183</note>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main">In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Celada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diaz-Mataix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Artigas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cereb. Cortex</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12853374</note>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">Electrophysiological characterization of 5hydroxytryptamine2 receptors in the rat medial prefrontal cortex</title>
		<author>
			<persName><forename type="first">Ashby</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Kasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><surname>Ry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">252</biblScope>
			<biblScope unit="page">171</biblScope>
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note>PubMed: 2137174</note>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex</title>
		<author>
			<persName><forename type="first">M</forename><surname>Amargos-Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bortolozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Serrats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Adell</forename><forename type="middle">A</forename><surname>Celada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Toth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mengod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Artigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cereb. Cortex</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">281</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14754868</note>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kuroki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ichikawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">972</biblScope>
			<biblScope unit="page">216</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12711095</note>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bortolozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diaz-Mataix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Scorza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Celada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Artigas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurochem</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">1597</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 16277612</note>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">Activation of 5-HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Gudelsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synapse</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page">202</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15266551</note>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Pehek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Mcfarlane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maguschak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Pluto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">888</biblScope>
			<biblScope unit="page">51</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11146051</note>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main">5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">652</biblScope>
			<biblScope unit="page">40</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 21118683</note>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main">Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function</title>
		<author>
			<persName><forename type="first">L</forename><surname>Abdallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bonasera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Hopf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">8156</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19553455</note>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main">DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Scruggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bubser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Deutch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">8846</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11102493</note>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Mice lacking 5-HT2A receptor are insensitive to many of the behavioral and physiological effects of hallucinogens</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Sealfon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Soc. Neurosci. Abs</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">799</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yuen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Ebersole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wurmbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Weisstaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Sealfon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">8836</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14523084</note>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">5-HT2 receptors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Leysen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Drug Targets CNS Neurol. Disord</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">11</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14965241</note>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">1671</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17493641</note>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Fluoxetine gradually increases [125I]DOI-labelled 5-HT2A/2C receptors in the hypothalamus without changing the levels of Gq-and G11-proteins</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Muma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Van De Kar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">775</biblScope>
			<biblScope unit="page">225</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9439849</note>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">RNA editing of the serotonin 2C receptor and expression of Galpha(q) protein: Genetic mouse models do not support a role for regulation or compensation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Canal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Mahautmr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sanders-Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Airey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurochem</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page">1136</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19154337</note>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: Influence of receptor reserve and relationship to agonist-directed trafficking</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cussac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Newman-Tancredi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Duqueyroix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pasteau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page">578</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12181434</note>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Phospholipase D activation by endogenous 5hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mcgrew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page">1339</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 12435801</note>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Regulation of 5-HT2A/C receptors and DOIinduced behaviors by protein kinase Cgamma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Bowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miyamoto-Ditmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page">441</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Raehal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Bohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page">18195357</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main">Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a beta-arrestin2/Src/Akt signaling complex in vivo</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Bohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">13513</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20926677</note>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Abbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Yadav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Arbuckle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Caron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">7124</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19494135</note>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Vaidya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Duman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">2785</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9092600</note>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Gewirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Terwilliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Duman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">317</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yoshii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Constantine-Paton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Neurosci</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">17515902</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">Changes in 5-HT2A-mediated behavior and 5-HT2A-and 5-HT1A receptor binding and expression in conditional brain-derived neurotrophic factor knock-out mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Santini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aznar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Knudsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rios</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page">1007</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20576498</note>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main">Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page">348</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21288474</note>
</biblStruct>

<biblStruct xml:id="b209">
	<monogr>
		<title level="m" type="main">BLAST Scoring Parameters</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gertz</surname></persName>
		</author>
		<ptr target="ftp://ftp.ncbi.nlm.nih.gov/blast/documents/developer/scoring.pdf" />
		<imprint>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>Published online</note>
</biblStruct>

<biblStruct xml:id="b210">
	<analytic>
		<title level="a" type="main">Assessment of the roles of serines 5.43 (239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Braden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">1200</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17715398</note>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main">Drug discovery targeting human 5-HT(2 C) receptors: Residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Canal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Cordova-Sintjago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Villa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Booth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">673</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 22020288</note>
</biblStruct>

<biblStruct xml:id="b212">
	<analytic>
		<title level="a" type="main">Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Loncharich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page">277</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 8114677</note>
</biblStruct>

<biblStruct xml:id="b213">
	<analytic>
		<title level="a" type="main">Species differences in 5-HT2A receptors: cloned pig and rhesus monkey 5-HT2A receptors reveal conserved transmembrane homology to the human rather than rat sequence</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kursar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta</title>
		<imprint>
			<biblScope unit="volume">1236</biblScope>
			<biblScope unit="page">201</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b214">
	<analytic>
		<title level="a" type="main">Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: Evidence for 5-HT(2A) receptor mediation of the HPA axis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hemrick-Luecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">162</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11804612</note>
</biblStruct>

<biblStruct xml:id="b215">
	<analytic>
		<title level="a" type="main">The selective serotonin (2A) receptor antagonist, MDL100,907, elicits a specific interoceptive cue in rats</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dekeyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Iob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hautefaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">552</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>PubMed: 11927180</note>
</biblStruct>

<biblStruct xml:id="b216">
	<analytic>
		<title level="a" type="main">Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dekeyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Girardon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">415</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10219979</note>
</biblStruct>

<biblStruct xml:id="b217">
	<analytic>
		<title level="a" type="main">Neuroendocrine evidence that (S)-2-(chloro-5fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5hydroxytryptamine(2C) receptor agonist</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Damjanoska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Muma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Carrasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kindel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Haskins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Shankaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>De Kar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="page">1209</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12604698</note>
</biblStruct>

<biblStruct xml:id="b218">
	<analytic>
		<title level="a" type="main">Old and new pharmacology: Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b&apos;] di pyrrole-1(2H)carboxamide)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dunlop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page">766</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19050173</note>
</biblStruct>

<biblStruct xml:id="b219">
	<analytic>
		<title level="a" type="main">Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gobert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rivet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lejeune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Newman-Tancredi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adhumeau-Auclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Nicolas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cistarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Melon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synapse</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">205</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 10819900</note>
</biblStruct>

<biblStruct xml:id="b220">
	<analytic>
		<title level="a" type="main">Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens</title>
		<author>
			<persName><forename type="first">P</forename><surname>De Deurwaerdere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Navailles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Spampinato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">3235</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15056702</note>
</biblStruct>

<biblStruct xml:id="b221">
	<analytic>
		<title level="a" type="main">In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">291</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11103883</note>
</biblStruct>

<biblStruct xml:id="b222">
	<analytic>
		<title level="a" type="main">Differences in the disposition and toxicity of 1-methyl-4-phenylpyridinium in cultured rat and mouse astrocytes</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><surname>Mj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Glia</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">329</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7890335</note>
</biblStruct>

<biblStruct xml:id="b223">
	<analytic>
		<title level="a" type="main">DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ichikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">907</biblScope>
			<biblScope unit="page">151</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11430898</note>
</biblStruct>

<biblStruct xml:id="b224">
	<analytic>
		<title level="a" type="main">Ligand-selective receptor conformations revisited: the promise and the problem</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kenakin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Pharmacol. Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">346</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12871667</note>
</biblStruct>

<biblStruct xml:id="b225">
	<analytic>
		<title level="a" type="main">Functional selectivity and biased receptor signaling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kenakin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">336</biblScope>
			<biblScope unit="page">296</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 21030484</note>
</biblStruct>

<biblStruct xml:id="b226">
	<analytic>
		<title level="a" type="main">Cellular assays as portals to seven-transmembrane receptor-based drug discovery</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Kenakin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discov</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">617</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19609267</note>
</biblStruct>

<biblStruct xml:id="b227">
	<analytic>
		<title level="a" type="main">m-chlorophenylpiperazine and mtrifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Grotewiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page">1122</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>PubMed: 7965773</note>
</biblStruct>

<biblStruct xml:id="b228">
	<analytic>
		<title level="a" type="main">mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Kennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dourish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Clifton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page">663</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14996544</note>
</biblStruct>

<biblStruct xml:id="b229">
	<analytic>
		<title level="a" type="main">Lorcaserin, a novel selective human 5hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grottick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Menzaghi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pharmacol. Exp. Ther</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page">577</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18252809</note>
</biblStruct>

<biblStruct xml:id="b230">
	<analytic>
		<title level="a" type="main">5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fiorella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Helsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page">237</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8748393</note>
</biblStruct>

<biblStruct xml:id="b231">
	<analytic>
		<title level="a" type="main">Agonist-trafficking and hallucinogens</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Sealfon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1017</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19275609</note>
</biblStruct>

<biblStruct xml:id="b232">
	<analytic>
		<title level="a" type="main">mCPP: An undesired addition to the ecstasy market</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Bossong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Brunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Van Dijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rigter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hoek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Niesink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">1395</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19304863</note>
</biblStruct>

<biblStruct xml:id="b233">
	<analytic>
	</analytic>
	<monogr>
		<title level="m">NDA 22-529, Briefing Document for FDA Advisory Committee Meeting</title>
		<imprint>
			<date type="published" when="2010-08-13">August 13. 2010</date>
			<biblScope unit="volume">356</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b234">
	<analytic>
		<title level="a" type="main">In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kloberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schedwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Rung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Carlsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural Transm</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="1511">2011. 1511</date>
		</imprint>
	</monogr>
	<note>PubMed: 21874578</note>
</biblStruct>

<biblStruct xml:id="b235">
	<analytic>
		<title level="a" type="main">In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Schiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Hacksell</surname></persName>
		</author>
		<author>
			<persName><surname>Ii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural Transm</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="1523">2011. 1523</date>
		</imprint>
	</monogr>
	<note>PubMed: 21866391</note>
</biblStruct>

<biblStruct xml:id="b236">
	<analytic>
		<title level="a" type="main">Inhibition of 5hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Shaughnessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hammond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schachter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Grahame-Smith</forename><surname>Dg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">573</biblScope>
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
	<note>PubMed: 6603593</note>
</biblStruct>

<biblStruct xml:id="b237">
	<analytic>
		<title level="a" type="main">Discriminative stimulus properties of hallucinogens and related designer drugs</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Glennon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">NIDA Res. Monogr</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b238">
	<analytic>
		<title level="a" type="main">Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fiorella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page">357</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 8584618</note>
</biblStruct>

<biblStruct xml:id="b239">
	<analytic>
		<title level="a" type="main">Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Benneyworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sanders</forename><forename type="middle">-</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="page">854</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 15645221</note>
</biblStruct>

<biblStruct xml:id="b240">
	<analytic>
		<title level="a" type="main">The 5-HT1A receptor and the stimulus effects of LSD in the rat</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Reissig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Eckler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page">197</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed: 16025319</note>
</biblStruct>

<biblStruct xml:id="b241">
	<analytic>
		<title level="a" type="main">Human psychopharmacology of N,N-dimethyltryptamine</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Strassman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav. Brain Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">121</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8788488</note>
</biblStruct>

<biblStruct xml:id="b242">
	<analytic>
		<title level="a" type="main">Psychedelics and schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Sealfon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Neurosci</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page">225</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19269047</note>
</biblStruct>

<biblStruct xml:id="b243">
	<analytic>
		<title level="a" type="main">Serotonin research: contributions to understanding psychoses</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Pharmacol. Sci</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">445</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 19086254</note>
</biblStruct>

<biblStruct xml:id="b244">
	<analytic>
		<title level="a" type="main">A biochemical and pharmacological suggestion about certain mental disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Woolley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Shaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">228</biblScope>
			<date type="published" when="1954">1954</date>
		</imprint>
	</monogr>
	<note>PubMed: 16589461</note>
</biblStruct>

<biblStruct xml:id="b245">
	<analytic>
		<title level="a" type="main">Modeling madness in mice: One piece at a time</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Arguello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gogos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">179</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 17015235</note>
</biblStruct>

<biblStruct xml:id="b246">
	<analytic>
		<title level="a" type="main">Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Arora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Neural. Transm-Gen</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b247">
	<analytic>
		<title level="a" type="main">The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Offord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nyberg</surname></persName>
		</author>
		<idno type="PMID">10434243</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Pharmacol</title>
		<imprint>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b248">
	<analytic>
		<title level="a" type="main">The pipeline and future of drug development in schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">904</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17667958</note>
</biblStruct>

<biblStruct xml:id="b249">
	<analytic>
		<title level="a" type="main">Synergistic effect of decreased opioid activity and sleep deprivation on head-twitch response in mice</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">D</forename><surname>Ionov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page">48</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b250">
	<analytic>
		<title level="a" type="main">Prenatal infection and schizophrenia: a review of epidemiologic and translational studies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Derkits</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page">261</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20123911</note>
</biblStruct>

<biblStruct xml:id="b251">
	<analytic>
		<title level="a" type="main">Effects of donepezil on DOI-induced head twitch response in mice: Implications for Tourette syndrome</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Hayslett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tizabi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Biochem. Be</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page">409</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b252">
	<analytic>
		<title level="a" type="main">Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rinaldi-Carmona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bouaboula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Congy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Oury-Donat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simiand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Casellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Soubrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Breliere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Fur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">246</biblScope>
			<biblScope unit="page">73</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>PubMed: 8354344</note>
</biblStruct>

<biblStruct xml:id="b253">
	<analytic>
		<title level="a" type="main">Functions of 5-HT2A receptor and its antagonists in the cardiovascular system</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nagatomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rashid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abul</forename><surname>Muntasir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Komiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page">59</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15500909</note>
</biblStruct>

<biblStruct xml:id="b254">
	<analytic>
		<title level="a" type="main">Therapeutic potential of 5-HT2C receptor ligands</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename><surname>Cremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sotty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scientific World Journal</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1870</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20852829</note>
</biblStruct>

<biblStruct xml:id="b255">
	<analytic>
		<title level="a" type="main">Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Monti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Today (Barc.)</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page">183</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20467592</note>
</biblStruct>

<biblStruct xml:id="b256">
	<analytic>
		<title level="a" type="main">The complex role of serotonin and 5-HT receptors in chronic pain</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bardin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">390</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b257">
	<analytic>
		<title level="a" type="main">Pharmacological targeting of the serotonergic system for the treatment of obesity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Garfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Heisler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Physiol</title>
		<imprint>
			<biblScope unit="volume">587</biblScope>
			<biblScope unit="page">49</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19029184</note>
</biblStruct>

<biblStruct xml:id="b258">
	<analytic>
		<title level="a" type="main">The role of serotonin receptor subtypes in treating depression: a review of animal studies</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lucki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="page">265</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21107537</note>
</biblStruct>

<biblStruct xml:id="b259">
	<analytic>
		<title level="a" type="main">Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mccann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jesse</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">218</biblScope>
			<biblScope unit="page">649</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21674151</note>
</biblStruct>

<biblStruct xml:id="b260">
	<analytic>
		<title level="a" type="main">Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Maclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Griffiths</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<date type="published" when="1453">2011. 1453</date>
		</imprint>
	</monogr>
	<note>PubMed: 21956378</note>
</biblStruct>

<biblStruct xml:id="b261">
	<analytic>
		<title level="a" type="main">Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Mcdougle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Price</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">402</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 12589395</note>
</biblStruct>

<biblStruct xml:id="b262">
	<analytic>
		<title level="a" type="main">Serotonergic drugs and valvular heart disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Baumann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin. Drug Saf</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">317</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19505264</note>
</biblStruct>

<biblStruct xml:id="b263">
	<analytic>
		<title level="a" type="main">Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Hufeisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page">2836</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11104741] References</note>
</biblStruct>

<biblStruct xml:id="b264">
	<monogr>
		<title/>
		<author>
			<persName><surname>Sprague-Dawley</surname></persName>
		</author>
		<imprint>
			<date>1.25-3.0, NR 5-9 [114,32,131,66</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b265">
	<monogr>
		<title/>
		<author>
			<persName><surname>Aston</surname></persName>
		</author>
		<idno>ICR 1.0</idno>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page">29</biblScope>
		</imprint>
	</monogr>
	<note>67,138] ICR 1.0, NR 25,26 [68,154</note>
</biblStruct>

<biblStruct xml:id="b266">
	<monogr>
		<title/>
		<author>
			<persName><surname>Aston</surname></persName>
		</author>
		<idno>MF1 1.0, NR 27 [141] 129Sv 2.0, NR 21</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b267">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Albino ICR</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">15</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b268">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Albino ICR 1.0, NR</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">9</biblScope>
		</imprint>
	</monogr>
	<note>140,252</note>
</biblStruct>

<biblStruct xml:id="b269">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Albino ICR</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">8</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b270">
	<monogr>
		<title level="m" type="main">Experiments using doses of, or close to 1.0 mg/kg were chosen for consistency. HTR counts began between 0 and 30 min after DOI injection. Results from observation periods greater than 10 min were divided to obtain a 10-min average. NR (not reported) Drug Test Anal</title>
		<imprint>
			<date type="published" when="2013-07-25">2013 July 25</date>
		</imprint>
	</monogr>
	<note>Results are averages from published reports. This list is not exhaustive, but is for illustrative purposes. Author manuscript; available in PMC</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
